

## Review Article

# The Effects of Vitamins and Micronutrients on *Helicobacter pylori* Pathogenicity, Survival, and Eradication: A Crosstalk between Micronutrients and Immune System

Ali Nabavi-Rad <sup>1</sup>, Mahsa Azizi <sup>1</sup>, Shaghayegh Jamshidizadeh <sup>1</sup>, Amir Sadeghi,<sup>2</sup>  
Hamid Asadzadeh Aghdaei,<sup>3</sup> Abbas Yadegar <sup>1</sup> and Mohammad Reza Zali<sup>2</sup>

<sup>1</sup>Foodborne and Waterborne Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>2</sup>Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

<sup>3</sup>Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

Correspondence should be addressed to Abbas Yadegar; a.yadegar@sbmu.ac.ir

Received 3 January 2022; Revised 19 February 2022; Accepted 25 February 2022; Published 16 March 2022

Academic Editor: Paulina Niedźwiedzka-Rystwej

Copyright © 2022 Ali Nabavi-Rad et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Helicobacter pylori* as a class I carcinogen is correlated with a variety of severe gastroduodenal diseases; therefore, *H. pylori* eradication has become a priority to prevent gastric carcinogenesis. However, due to the emergence and spread of multidrug and single drug resistance mechanisms in *H. pylori*, as well as serious side effects of currently used antibiotic interventions, achieving successful *H. pylori* eradication has become exceedingly difficult. Recent studies expressed the intention of seeking novel strategies to improve *H. pylori* management and reduce the risk of *H. pylori*-associated intestinal and extragastrintestinal disorders. For which, vitamin supplementation has been demonstrated in many studies to have a tight interaction with *H. pylori* infection, either directly through the regulation of the host inflammatory pathways or indirectly by promoting the host immune response. On the other hand, *H. pylori* infection is reported to result in micronutrient malabsorption or deficiency. Furthermore, serum levels of particular micronutrients, especially vitamin D, are inversely correlated to the risk of *H. pylori* infection and eradication failure. Accordingly, vitamin supplementation might increase the efficiency of *H. pylori* eradication and reduce the risk of drug-related adverse effects. Therefore, this review aims at highlighting the regulatory role of micronutrients in *H. pylori*-induced host immune response and their potential capacity, as intrinsic antioxidants, for reducing oxidative stress and inflammation. We also discuss the uncovered mechanisms underlying the molecular and serological interactions between micronutrients and *H. pylori* infection to present a perspective for innovative in vitro investigations, as well as novel clinical implications.

## 1. Introduction

As a Gram-negative pathogen, *Helicobacter pylori* (*H. pylori*) is uniquely adapted to survive in the acidic environment of the human stomach [1]. *H. pylori* infection most frequently acquires in childhood and remains generally asymptomatic with long-term clinical sequelae. The incidence of the infection is over half of the world's pop-

ulation and is highly dependent on geographical origin and socioeconomic status [2].

*H. pylori* infection leads to gastric mucosal damage by means of its virulence factors, induction of host proinflammatory cytokines, reactive oxygen species (ROS), and reactive nitrogen species [3]. The mucosal damage can progress to gastritis, peptic ulcer disease (PUD), dyspepsia, gastric mucosa-associated lymphoid tissue (MALT)

lymphoma, or gastric carcinoma [4]. Considering *H. pylori* as the major cause of gastric carcinoma, the World Health Organization (WHO) lists *H. pylori* as a class I carcinogen [5]. Despite the reduction in infection prevalence owing to antibiotic usage, the eradication of *H. pylori* has become an important matter to prevent gastric cancer [6].

However, it has been well established, achieving successful eradication of *H. pylori* infection is exceedingly difficult [7]. As the first-line of treatment, international guidelines suggest four drug combinations with two or three types of antibiotics for 10-14 days [8]. Even the simplest regimen, proton-pump inhibitor (PPI) and amoxicillin may come up with serious adverse effects including type 2 diabetes and increase the risk of gastric adenocarcinoma [9–11]. As a result, currently used treatments are not sufficiently effective, so alternative therapies need to be developed [12].

Even though there are contrary opinions on the effect of vitamin administration, several studies demonstrated that *H. pylori* infection decreases certain vitamin concentration in the gastric juice [13]. Many studies even showed a substantial increase in the eradication rate by vitamin supplementation in a dose-dependent manner [14]. On the other hand, various minerals are reported to directly or indirectly regulate *H. pylori* colonization and pathogenicity [13]. In this review, we discuss the current knowledge on how vitamins and minerals may link to *H. pylori* eradication or the host immune defenses against this recalcitrant pathogen. We also highlight the latest findings regarding vitamin and mineral interventions affecting the pathogenesis of *H. pylori* to elucidate the importance of micronutrients supplementation, providing a hopeful perspective for the development of potential preventive and therapeutic applications in clinical practice.

## 2. *H. pylori* and Immune System

The gastrointestinal mucosa, frequently encountered with antigens and food allergens, is equipped by a mucosal immune system to protect it against harmful foreign materials [15]. The gastrointestinal mucous layer and epithelial layer form the mucosal surface which is supported by the lamina propria underneath the epithelium [16]. Gastrointestinal immune components can be classified into either inductive sites including the mesenteric lymph nodes (MLN) and the gut-associated lymphoid tissues (GALT) or effector sites including the gut lamina propria and epithelial layer, in which they undergo maturation or localization, respectively [17]. There are antibodies, cytokines, chemokines, and their receptors in gut mucosal effector sites to provide immune protection and maintain homeostasis [18].

*H. pylori* is correlated with chronic inflammation, causing structural changes in gastric mucosa including glandular atrophy and intestinal metaplasia (IM) and developing gastric carcinoma [19]. The main explanation of inflammatory changes stimulated by this pathogen is the enhanced production of interleukin-1 $\beta$  (IL-1 $\beta$ ), IL-8, IL-12, tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), and ROS [20]. As a result of *H. pylori* infection, neutrophils, eosinophils, mast cells, and dendritic cells (DCs) infiltrate to the mucosal epithelium to

provoke active inflammation [21]. Moreover, by the attraction and activation of neutrophils, *H. pylori* enhances the production of TNF- $\alpha$ , IL-1 $\beta$ , IL-8, ROS, macrophage inflammatory protein-1 $\alpha$  (MIP-1 $\alpha$ ), and MIP-1 $\beta$  [22]. IL-1 $\beta$  increases the adhesion of neutrophils to endothelial cells by stimulating the expression of adhesion molecules. Both TNF- $\alpha$  and IL-1 $\beta$  enhance the secretion of prostacyclin (PGI<sub>2</sub>), prostaglandin E<sub>2</sub> (PGE<sub>2</sub>), and platelet-activating factor (PAF) from endothelial cells [23]. As lipid mediators, PGE<sub>2</sub> and PGI<sub>2</sub> have a role in the regulation of vascular function and inflammation. In particular, PGE<sub>2</sub> regulates the permeability of endothelial cells, and PGI<sub>2</sub> exhibits a protective impact during the resolution phase of inflammation [24]. The PAF signaling cascade activates a variety of intracellular pathways in inflammatory and immune cells and changes cellular function and phenotype to trigger or expand inflammatory response [25].

IL-8, a chemokine that plays a critical role in *H. pylori*-induced inflammation, activates the CD11b/CD18 dimer to form a complex with neutrophils. This complex binds to ICAM-1 on the membrane of vascular endothelial cells and forms a tetramer; therefore, IL-8 recruits neutrophils and promotes their adhesion to endothelial cells [26]. As a result, excessive production of IL-8 leads to neutrophil influx and inflammation [27]. On the other hand, ROS including superoxide anion (O<sub>2</sub><sup>-</sup>), hydroxyl radical (OH $\bullet$ ), hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), and singlet oxygen (<sup>1</sup>O<sub>2</sub>), are natural by-products of normal cell activity, mainly generated in the respiratory chain in mitochondria and photochemical and enzymatic reactions [28]. ROS, in their normal concentration, act as the intermediate in cell signaling pathways. On the contrary, the overproduction of ROS is associated with various diseases, inflammation, DNA damage, and interfering cell signaling pathways. The homeostasis of ROS is a major priority for living organisms to prevent genome instability and cell death [29].

Depending on the bacterial virulence genotype, *H. pylori* infection results in excessive production of ROS and developing oxidative stress [30]. *H. pylori* bacteria, especially cytotoxin-associated gene A (CagA)-positive strains, induce the activation of the enzyme mitogen oxidase-1 (Mox1) in epithelial cells, leading to enhanced generation of superoxide anions [31]. It is long known that releasing various inflammatory mediators, such as chemokines which are chemoattractants of neutrophils from *H. pylori*, stimulates neutrophils to produce ROS in a normal concentration [32]. Because one of the major immune responses of neutrophils is the generation of oxidative bursts by NADPH oxidase to kill the invasive pathogen, persistent inflammatory mediators increase the risk of oxidative stress [33]. Moreover, *H. pylori* neutrophil-activating protein (HP-NAP), released from *H. pylori* possibly by autolysis, induces the overexpression of ROS and chemokines [22].

Macrophage chemotactic protein-1 (MCP-1) is released from epithelial cells to induce the recruitment of macrophages and consequently release IL-1 $\beta$  as an inflammatory response. *H. pylori* infection promotes the expression of MCP-1. Accordingly, macrophage activation and excessive IL-1 $\beta$  secretion lead to gastric inflammation [34]. Activated

macrophages also develop oxidative stress by enhanced ROS production, mainly through NADPH oxidase-2, xanthine oxidase, and the mitochondrial electron transport chain [35]. It is suggested that *H. pylori* lipopolysaccharide (LPS) might activate the macrophages. However, the meticulous effect of *H. pylori* LPS on macrophage activation is yet to be elucidated [36, 37].

In gastric epithelial cells, vascular endothelial cells or immune cells, especially macrophages, *H. pylori* promotes the production of inducible nitric oxide synthase (iNOS) which stimulates nitric oxide (NO) production. As a highly reactive compound, NO frequently reacts with  $O_2^-$  to generate highly toxic peroxynitrite (ONOO<sup>-</sup>) [38]. However, *H. pylori* can inhibit the bactericidal activity of ONOO<sup>-</sup> by converting it to nitrosoperoxy carbonate (ONOOCO<sub>2</sub><sup>-</sup>) with urease product CO<sub>2</sub>; therefore, it causes collateral damage to host cells and does not eliminate *H. pylori* [39]. On the other hand, *H. pylori* is equipped with catalase and superoxide dismutase to detoxify ROS and also able to downregulate nitric oxide generation by means of arginase enzyme [40].

The innate immune system as the first-line of defense is equipped with recognition mechanisms, allowing detection and response to antigens without prior recognition [41]. *H. pylori* contains pathogen-associated molecular patterns (PAMPs) such as peptidoglycan, LPS, lipoproteins, and flagellins which are recognized by pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs), C-type lectin receptors (CLRs), NOD-like receptors (NLRs), and RIG-like receptors (RLRs) [42]. PAMP detection leads to multiple signaling pathways that increase nuclear factor kappa B (NF- $\kappa$ B) and activated protein-1 (AP-1) activation and immune effector's expression [43]. NF- $\kappa$ B and AP-1 are transcriptional factors, regulating a variety of gene expressions that contribute to important cellular activity, such as cell proliferation, apoptosis, and the innate and adaptive immune responses [44, 45]. To bind DNA and regulate gene transcription, NF- $\kappa$ B and AP-1 must be activated and translocated from the cytoplasm to the nucleus. The major activators for NF- $\kappa$ B and AP-1 by *H. pylori* are CagA and LPS [46, 47]. Adhesion molecules of *H. pylori*, antigen binding adhesion A (BabA), sialic acid binding adherence A (SabA), or outer membrane protein Q (HopQ), allow attachment of the bacteria to gastric epithelial cells [48]. LPS binds to TLR4, a member of signal transduction proteins, to induce the expression of transcriptional factors including NF- $\kappa$ B and AP-1 mostly in macrophages and gastric epithelial cells [49]. On the other hand, CagA needs to be injected into the host cell by type IV secretion system (T4SS) machinery to interact with intramembrane hepatocyte growth factor (HGF) receptor Met or epidermal growth factor receptor (EGFR) for upregulation of NF- $\kappa$ B and AP-1 [50, 51]. The activation of NF- $\kappa$ B and AP-1 stimulates the transcription of inflammatory mediators such as ROS and cyclooxygenase-2 (COX-2), inflammatory cytokines such as IL-8 and IL-6, and tumor necrosis factor receptor-associated factor (TRAF) genes, resulting in several cellular proliferation and damages [52, 53].

To survive the low pH (1.5 to 3.5) [54] environment of the stomach, *H. pylori* catalyzes the hydrolysis of urea by

urease to produce ammonia (NH<sub>3</sub>), thereby buffering the cytoplasm, periplasm, and immediate environment surrounding the bacteria. The urease is comprised of two major subunits UreA and UreB, encoded by the urease operon, accessory proteins for maturation, and two pivotal Ni<sup>2+</sup> ions for activation [55]. Independent to enzymatic activity, urease binds to the CD74 receptor on gastric epithelium cells to activate inflammatory pathways, leading to enhanced IL-8, IL-4, and T helper (Th) 1 cytokine secretion, NF- $\kappa$ B and macrophage activation, epithelial tight junction interference, and platelet aggregation [56].

*H. pylori* strains, possessing virulence factors such as CagA and vacuolization cytotoxin A (VacA), elevate the risk of atrophic gastritis and gastric cancer. Using a T4SS apparatus which is encoded by *cag* pathogenicity island (*cagPAI*), *H. pylori* injects CagA oncoprotein into host cells and mainly activates NOD1 [57]. Consequently, CagA increases the activation of transcription factors such as NF- $\kappa$ B, AP-1, and mitogen-activated protein kinase (MAPK) and IL-8 expression [58]. Moreover, CagA possibly permits VacA to break into the gastric submucosa and connect with macrophages, DCs, and B and T cells by opening the tight junctions [59]. VacA can prevent T cell activation and proliferation by downregulation of nuclear factor of activated T cells (NFAT) and therefore blocking the secretion of IL-2 [60].

### 3. *H. pylori* and Vitamins

**3.1. Vitamin D.** Vitamin D, a fat-soluble vitamin, has few dietary sources, and thereby, the primary route of obtaining this vitamin is through dermal synthesis after ultraviolet-B (UVB) radiation [61]. The two primary forms of vitamin D are vitamin D<sub>2</sub> and vitamin D<sub>3</sub>, formed from ergosterol and 7-dehydrocholesterol by UVB radiation, respectively [62]. Vitamins D<sub>2</sub> and D<sub>3</sub> are prohormones and biologically inactive. They need a 2-step enzymatic hydroxylation process to be activated [63]. The first step is performed by 25-hydroxylase in the liver, converting the components to 25 (OH) D (calcidiol). Then, the 25 (OH) D undergoes 1 $\alpha$ -hydroxylation mainly in the kidney to form 1, 25 (OH)<sub>2</sub> D (calcitriol), the most active form of vitamin D [64]. It has been demonstrated that cytokines such as interferon-gamma (IFN- $\gamma$ ) stimulate the production of 1, 25 (OH)<sub>2</sub> D by monocytes [65].

The genomic actions of vitamin D, such as downregulation of IL-2 and IFN- $\gamma$  expression by inhibition of transcription factors, are through vitamin D receptor (VDR), a member of nuclear hormone receptor family, which will further bind to specific DNA regions named vitamin D response elements (VDRE) [66]. The nongenomic activities of vitamin D include calcium homeostasis and regulation of hormone secretion, immune function, and cellular proliferation [67]. Although the whole molecular mechanisms of vitamin D activity are yet to be discovered, it has been suggested that vitamin D regulates both transcellular and paracellular calcium absorptions in the intestine [68]. Vitamin D induces calcium uptake across the brush border through calcium selective channel TRPV6. It also

increases the production of calbindin, the calcium-binding protein, to stimulate calcium transport through the cell. Vitamin D stimulates the generation of calcium pump as transcellular actions and downregulates cadherin 17 and aquaporin 8 as paracellular activities [69]. In the case of calcium homeostasis, vitamin D also regulates the calcium reabsorption in the distal tubule of the kidney [70]. Vitamin D downregulates parathyroid hormone secretion but stimulates insulin secretion, downregulates cellular proliferation but stimulates cellular differentiation such as the osteoblast by regulating the synthesis of collagen and alkaline phosphatase proteins [71, 72].

**3.2. Vitamin D and Immune Function.** Micronutrients including vitamin A, D, C, E, B6, B9, B12, zinc, iron, copper, nickel, and selenium play a key role in immune responses [73]. Cathelicidin antimicrobial peptide (CAMP) and  $\beta$ -defensin, mainly expressed and stored in epithelial cells and macrophages, demonstrate antibacterial actions against Gram-negative and Gram-positive bacteria and fungi [74, 75]. Calcitriol boosts the effect of antimicrobial proteins of macrophages and monocytes such as CAMP and  $\beta$ -defensin, regulating gut microbiota composition and preserving the normal bacterial community, therefore supporting the integrity of the gut barrier [76, 77]. On the other hand, it enhances the differentiation of monocytes to macrophages and boosts the movement and phagocytic ability of macrophages [78]. By increasing the expression of anti-inflammatory cytokines, calcitriol downregulates the production of IFN- $\gamma$  and proinflammatory cytokines [79]. Tight junction CLDN2 gene is a direct target of VDR; therefore, vitamin D increases the expression of tight junction protein that plays a major role in intestinal barrier function and homeostasis [80]. It has been also reported that vitamin D plays a pivotal role in preserving renal epithelial barrier function [81].

**3.3. The Effect of Vitamin D on *H. pylori* Infection and Eradication.** Vitamin D was found to suppress the *H. pylori*-induced production of proinflammatory cytokines including IL-1, IL-2, IL-6, IL-8, and TNF- $\alpha$  (Figure 1) [82]. Dauletbaev et al. similarly reported that vitamin D administration in the cell culture system suppresses the production of IL-8 in hyperinflammatory macrophages independent of the DUSP1 gene (an anti-inflammatory gene that partly regulates IL-8 production) [83]. A recent study demonstrated that vitamin D supplementation leads to downregulation of IL-8 in *H. pylori*-infected mice, in both wild type and VDR knockdown [84].

Antimicrobial peptides (AMPs) have a variety of inhibitory effects against pathogens and play a major part in the innate immune system of many organisms [85]. Although the exact mechanisms are yet to be discovered, Merriman et al. exhibited that vitamin D enhances the expression of multiple genes of  $\beta$ -defensin in vivo [86]. In humans, IL-1 $\beta$  and TLR activation are required for vitamin D to upregulate  $\beta$ -defensin [87]. Vitamin D also increases the expression of VDR which positively upregulates the production of vitamin D in the body; moreover, the vitamin D/VDR

complex will further bind to CAMP promotor and significantly enhance its expression [88, 89]. Guo et al. indicated that the presence of small interfering (si) VDR and siCAMP in the individuals might reject the theory that vitamin D has antibacterial activity [89]. However, by regulating the expression of CAMP and  $\beta$ -defensin, vitamin D has a crucial role in the immune response against various pathogens including *H. pylori* [90].

As a transmembrane glycoprotein, EGFR is involved in various cellular activities including proliferation, differentiation, and apoptosis which highlights the significance of this transmembrane receptor in mucosal defense. On the other hand, EGFR activation is of great significance to inflammatory and repair processes such as MAPK phosphorylation [91]. Consequently, EGFR not only mediates *H. pylori*-induced inflammation but also plays a crucial role in lung cancer and it has been discovered that vitamin D supplementation comes up with a possible advantage in the treatment. As a result, it is a possibility that vitamin D inhibits EGFR in *H. pylori*-infected individuals and suppresses the inflammation [92, 93]. In a dose-dependent manner, it also appears that vitamin D supplementation significantly reduces the CagA expression and suppresses *H. pylori*-induced production of IL-6 and IL-8 in animal models. Subsequently, vitamin D might be able to suppress *H. pylori*-induced inflammation [84].


Autophagosome fusion with lysosomes forms autophagolysosomes, which eliminates pathogens after their detection by the innate immune system [94]. *H. pylori* inhibits the lysosomal function by decreasing the lysosomal clearance of infected autophagosomes, resulting in bacterial survival [95]. Hu et al. demonstrated that vitamin D restores the impaired lysosomal activity of epithelial cells through stimulating membrane receptor PDIA3, leading to the redistribution of PDIA3-STAT3 complex into the nucleus and thereby enhancing the production of MCOLN3 protein, both in vitro and in vivo [96]. MCOLN3 channel is responsible for Ca<sup>2+</sup> trafficking which has a pivotal role in lysosomal acidification [97]. Consequently, downregulated expression of MCOLN3 protein by *H. pylori* can be normalized by vitamin D treatment, leading to the elimination of *H. pylori* [96].

VDP1, vitamin D3 decomposition product, destabilizes the membrane structure of *H. pylori* and lyses the bacterial cell independent of blocking the cellular metabolism through binding to dimyristoyl phosphatidylethanolamine (DMPE) in membrane lipid composition of *H. pylori* [98]. The anti-*H. pylori* effect of VDP1 is extremely selective and commonplace bacteria can survive even in a high concentration of VDP1 [99].

Vitamin D upregulated protein 1 (VDUP1), playing several roles in a variety of cellular processes such as the suppression of TNF- $\alpha$ -induced NF- $\kappa$ B activation, is upregulated by vitamin D supplementation [100, 101]. In animal models, VDUP1 reduces *H. pylori*-induced gastric carcinogenesis by regulating the maturation and cytotoxicity of natural killer (NK) cells and downregulating the expression of TNF- $\alpha$ , NF- $\kappa$ B, and COX-2 [102, 103].

Regarding the *H. pylori* infection in infants and toddlers, Gao et al. demonstrated that the prevalence of vitamin D





**FIGURE 1: The effect of micronutrients on *H. pylori* pathogenesis. (a) *H. pylori* can invade epithelial cells and interact with epidermal growth factor receptor (EGFR), toll-like receptor 4 (TLR4), and mitogen oxidase-1 (Mox1), thereby stimulating the activation of transcriptional factors and the production of reactive oxygen species (ROS). *H. pylori* neutrophil-activating protein (HP-NAP) and LPS lead to neutrophil activation and promotion of macrophage inflammatory responses, respectively. However, vitamin D and A interfere with CagA expression and ROS-mediated mitogen-activated protein kinase (MAPK) activation, respectively. Furthermore, vitamin D3 decomposition product (VDP1) lyses the bacterial cell and inhibits the colonization of *H. pylori*. Magnesium downregulates the activation of nuclear factor kappa B (NF-κB) and activated protein-1 (AP-1); therefore, suppressing the host inflammatory responses. (b) Neutrophil activation promotes the production of tumor necrosis factor-α (TNF-α), interleukin 8 (IL-8), IL-1β, and ROS. Macrophage chemotactic protein-1 (MCP-1) stimulates the infiltration of macrophages and thereby increases the concentration of inducible nitric oxide synthase (iNOS), IL-1β, and ROS in the gut lamina propria. The infected epithelial cells overexpress proinflammatory cytokines such as cyclooxygenase-2 (COX-2), IL-8, and ROS. The overproduction of hepcidin in the liver, owing to *H. pylori* infection, interferes with the iron release from the macrophages. Vitamin D and A promote the expression of Vitamin D upregulated protein 1 (VDUP1) and immunoglobulin A (IgA), respectively. Regarding macrophages, vitamin D inhibits IL-8 secretion, increases β-defensin production through TLR activation and provokes the production of cathelicidin antimicrobial peptide (CAMP) by vitamin D receptor (VDR). Vitamin D regulates the reduced function of autolysosome and consequently stimulates *H. pylori* degradation in gastric epithelial cells. Moreover, this vitamin promotes the gut epithelial barrier by increasing the expression of tight junctions. On the other hand, vitamin C can reduce N-nitroso compound formation from nitric oxide (NO) and thereby inhibits carcinogenesis. (c) As chronic inflammation results in carcinogenesis, vitamin C promotes collagen production and prevents tumor metastasis. On the other hand, vitamin E reduces neutrophil adhesion and the secretion of prostaglandin E2 (PGE2) from tumor cells. Vitamin A and B6 induce B and T cell gut-homing, and selenium provokes the antibody secretion from B cells. Vitamin A is also involved in the production of transforming growth factor-beta (TGF-β) in the dendritic cells (DCs).**

deficiency in children with *H. pylori*-positive antibody was more likely to occur than the *H. pylori*-negative antibody group [104]. Concerning adults, Shafrir et al. demonstrated that vitamin D was inversely related to *H. pylori* infection and the possibility of infection was significantly higher in vitamin D-deficient patients than vitamin D-sufficient patients [105]. A recent study similarly reported that in the old patients, aged 65 years, with sarcopenia, *H. pylori* infection led to vitamin D deficiency and the prevalence of infection was significantly higher in vitamin D-deficient patients [106]. Twenty years of  $1\alpha$ -hydroxyvitamin D3 supplementation resulted in a significantly lower *H. pylori* infection rate in subjects [107]. In the case of *H. pylori* eradication, among 150 *H. pylori*-infected patients, Shahawy et al. reported that the mean level of 25 (OH) D was substantially higher in the successful eradication group [108]. Having a serum vitamin D level < 10 ng/mL is possibly an independent risk factor for the treatment failure of *H. pylori* infection [109].

Although there are controversial results regarding the efficiency of vitamin D supplementation during *H. pylori* eradication, multiple cohort studies and clinical trials mostly reported a reverse interaction between serum vitamin D level and *H. pylori* infection as it is supported by several in vitro antipathogenic activities of this vitamin (Table 1). Furthermore, vitamin D administration might reduce the adverse effects of antibiotic treatment by preserving the normal gut microbiota composition.

**3.4. Vitamin A.** Vitamin A, a group of fat-soluble vitamins, was discovered in 1906, and owing to the crystallization of vitamin A in 1937, it was synthesized for the first time by Otto Isler in 1947 [111]. This vitamin is essential in preserving physiological activities such as vision, growth, and integrity of epithelial and mucosal tissues as well as regulating the host immune responses [112]. The most common forms of food-derived vitamin A are retinol (vitamin A1) and carotenoids (provitamin A) which are transferred to hepatic stellate cells (HSCs) and then stored as retinyl ester [113]. Retinol, especially found in animal foods including dairy, fish, egg yolks, and meat, is converted to retinal by retinyl ester and thereby plays a key role in low-light and color vision and mitochondrial oxidative phosphorylation [114, 115]. By being converted to retinoic acid (RA), a hormone-like growth factor, retinol stimulates the differentiation and growth of epithelial cells and maintains the homeostasis of the skin and bone [116, 117].

Carotenoids or provitamin A are a complex collection of more than 850 naturally existing pigments, which are produced by plants, algae, and photosynthetic bacteria [118]. As the human body is incapable of carotenoid synthesis, its bioavailability highly depends on dietary resources [119].  $\beta$ -carotene is the most common provitamin A [120] and its bioavailability is affected by several factors, such as food processing, nutritional matrix composition, and gastrointestinal health status [121]. Although  $\beta$ -carotene can scavenge free radicals, it is incapable of being regenerated after decomposition; therefore, it is suggested that the main bioactivity of  $\beta$ -carotene is that of a provitamin A [122].

**3.5. Vitamin A and Immune Function.** The active metabolite of vitamin A plays a major role in epithelial tissue differentiation and mucosal immune responses [123]. RA induces gut-homing specificity in B and T cells by increasing the expression of chemokine receptor CCR9 on these cells, thereby promoting their trafficking to intestinal tissue [124]. Vitamin A also affects T cell regulation and differentiation into different T helpers, including Th1, Th2, and Th17 cells [125]. It has been discovered that RA enhances the secretion of transforming growth factor-beta (TGF- $\beta$ ) from DCs, therefore regulating the adaptive immune response [126] and increasing the release of immunoglobulin A (IgA) in the intestinal mucosa [127]. Although it is known that vitamin A has an impact on neutrophil differentiation and NK cell cytotoxicity, the exact mechanism remains elusive [128, 129].

**3.6. The Effect of Vitamin A on *H. pylori* Infection.** Beta carotene, the most important source of vitamin A production in the body [130], is an effective antioxidant inhibiting *H. pylori*-induced gastric inflammation, which not only reduces ROS but also interferes with the ROS-mediated inflammatory signaling such as MAPK and NF- $\kappa$ B activation; consequently,  $\beta$ -carotene suppresses iNOS and COX-2 production. It also prevents neutrophil recruiting by reducing the expression of inflammatory mediators such as IL-8 [131]. Park et al. demonstrated that as a result of inhibiting ROS generation and NF- $\kappa$ B activation,  $\beta$ -carotene reduces the *H. pylori*-induced production of TRAF1 and TRAF2 and cell proliferation in *H. pylori*-infected AGS cells [132]. A recent study investigated *H. pylori*-induced MMP expression and cell invasion and reported that  $\beta$ -carotene prevents MAPK-mediated MMP-10 expression and *H. pylori* invasion to AGS cell line through suppression of oxidative stress and upregulation of PPAR- $\gamma$ -mediated catalase production [133]. Kim et al. reported that although exposure of AGS cells with low concentration (5 and 10  $\mu$ M) of  $\beta$ -carotene suppresses c-myc and cyclin E, a 10-fold higher concentration range (50 and 100  $\mu$ M) induces ROS production and apoptosis, decreases DNA repair protein expression, and activates caspase-3 [134].

Astaxanthin, the most efficient immune promoter among carotenoids, shifts the T helper cells regulation to Th2 as *H. pylori* changes the immunity balance between Th1 and Th2 toward Th1. Even though astaxanthin inhibits *H. pylori* growth and gastric inflammation, it does not decrease cytokine concentration in the infected tissue [135]. Furthermore, an in vitro study exhibited that astaxanthin can prevent *H. pylori*-induced apoptosis as well as its intracellular replication through regulating AGS cell line autophagy [136].

Although the role of provitamin A is not fully understood, several studies indicated a protective role for  $\beta$ -carotene in suppressing *H. pylori*-induced inflammation. On the other hand, the regulatory role of astaxanthin on the defect autophagy of infected cells highlights the importance of this carotenoid in preventing gastric adenocarcinoma.

TABLE 1: The effects of vitamin D deficiency on *H. pylori* eradication.

Country	Study design	Eradication regimen	Antioxidant	Confirming <i>H. pylori</i> infection test	Confirming <i>H. pylori</i> eradication Time (weeks after therapy)	Eradication rate		Antioxidant level (ng/mL)		References			
						Method	Successful eradication	Failed eradication	Successful eradication		Failed eradication	P value	P value
Egypt	Randomized controlled trial	Amoxicillin 1000 mg bid, clarithromycin 500 mg bid, esomeprazole 20 mg bid, 14 days	25 (OH) D	ME-NBI, SAT	SAT	4	105/150	45/150	NA	27.41 ± 7.1	14.7 ± 4.5	P < 0.001	[108]
China	Randomized controlled trial	Amoxicillin 1000 mg bid, clarithromycin 500 mg bid, colloidal bismuth tartrate capsule 220 mg bid, esomeprazole 40 mg bid or rabeprazole 20 mg bid, 14 days	25 (OH) D	UBT	UBT	4-8	355/415	60/415	NA	322/355 ≥ 10 (ng/mL), 33/355 < 10 (ng/mL)	13/60 ≥ 10 (ng/mL), 47/60 < 10 (ng/mL)	P < 0.005	[109]
China	Randomized controlled trial	Amoxicillin 1000 mg bid, clarithromycin 500 mg bid, bismuth potassium citrate 220 mg bid, esomeprazole 20 mg bid, 14 days	25 (OH) D	UBT	UBT	4	124/160	36/160	P = 0.677	19.87 ± 6.35	15.09 ± 7.72	P < 0.05	[110]
Israel	Randomized controlled trial	Based on the individual conditions	25 (OH) D	UBT, SAT	UBT, SAT	0	45,821/61,921	16,100/61,921	NA	19.34 ± 9.55	18.64 ± 9.61	P < 0.001	[105]

qd, once a day; bid, twice a day; tid, three times a day; qid, four times a day; UBT, urea breath test; SAT, stool antigen test; ME-NBI, magnifying endoscopy with narrow band imaging; NA, not available.

**3.7. Vitamin C.** Albert Szent-Györgyi discovered vitamin C in the 1920s and found its relevance in the treatment and prevention of scurvy [137]. Owing to the nonfunctional gene encoding L-gluconolactone oxidase, this micronutrient classifies as an essential nutritional vitamin [138]. Vitamin C, a water-soluble antioxidant, is mainly present in its reduced form as ascorbic acid or oxidized form as dehydroascorbic acid and takes part in a variety of human bioactivity [139]. It is involved in the synthesis of collagen, noradrenaline, adrenaline, peptide hormones, and carnitine. Moreover, vitamin C contributes to gene transcription, regulation of translation, epigenetic mechanisms involved in the control of gene expression, elimination of ROS, and favoring iron absorption. However, excessive accumulation of this vitamin induces its pro-oxidant rather than antioxidant activity [140].

**3.8. Vitamin C and Immune Function.** In a dose-dependent manner, vitamin C promotes the proliferation of lymphocytes and increases antibody generation [141]. Vitamin C is involved in neutrophil and monocyte movements, neutrophil chemotaxis, NK cell activities, and lymphocyte delayed-type hypersensitivity (DTH) response [142]. Through contribution in apoptosis and clearance of the infection sites from spent neutrophils by macrophages, vitamin C prevents necrosis, neutrophil extracellular trap (NET) formation, and tissue damage [143]. High-dose supplementation of vitamin C is correlated with the increased relative abundance of the Lachnospiraceae bacterial family, which is predominant in the gut microbiota composition of healthy individuals and known to possess multiple anti-inflammatory and antioxidant effects [144].

**3.9. The Effect of Vitamin C on *H. pylori* Infection.** As an antioxidant, vitamin C can scavenge and eliminate ROS and reduce oxidative stress [145]. On the other hand, it is reported that vitamin C administration during acid-suppressive treatment can downregulate the overexpression of ROS, mucosal IL-8, and neutrophil infiltration in *H. pylori*-infected patients and possibly inhibit corpus gastritis [146]. It is long known that by inhibiting the generation of N-nitroso compounds that are strong carcinogens, vitamin C suppresses gastritis [147]. Another mechanism by which vitamin C can prevent gastric malignancy is that it increases apoptosis and G0/G1 cell cycle arrest in infected cells [148]. Vitamin C not only directly interferes with the energy metabolism or epigenome regulation of cancer stem cells but also stimulates collagen synthesis and indirectly suppresses tumor metastasis [149].

Although some studies decline the impact of *H. pylori* infection on vitamin C level [150], it has been recently indicated that infection with *H. pylori* impairs the secretion of vitamin C from serum to the stomach and thus decreases gastric juice vitamin C level [151]. According to Capurso et al., the observed reduction in gastric juice vitamin C levels in individuals with gastric atrophy is related to intragastric pH [152]. Intragastric pH level rises when hypochlorhydria develops, as is typical in gastric atrophy; thereby, ascorbic acid is transformed to the less active form of dehydroascorbic acid [153].

However, tissue vitamin C concentration is not affected by *H. pylori* infection and might still have a protective impact against gastritis [154]. It is noteworthy that CagA-positive strains have a significantly higher impact on vitamin C levels than CagA-negative strains [155]. On the other hand, vitamin C supplementation has a higher impact on CagA-positive strains [156]. Even though several studies examined the relation between vitamin C supplementation and *H. pylori* eradication and reported the restored gastric juice concentration of vitamin C after *H. pylori* eradication, the results of oral administration of vitamin C are still controversial [157].

Despite the contradictory reports regarding vitamin C interaction with *H. pylori*, this micronutrient plays a pivotal role in regulating the immune response and preventing tumor metastasis. However, high-dose administration of vitamin C might act as pro-oxidant rather than antioxidant and cause collateral damages.

**3.10. Vitamin E.** Vitamin E refers to a group of four tocopherols ( $\alpha$ -,  $\beta$ -,  $\gamma$ -, and  $\delta$ -tocopherols) as well as four tocotrienols ( $\alpha$ -,  $\beta$ -,  $\gamma$ -, and  $\delta$ -tocotrienols) found in food. These forms cannot be transformed into each other, and  $\alpha$ -tocopherol meets the requirement of vitamin E in the human body [158]. The bioavailability of vitamin E is affected by dietary, absorption, metabolism, lifestyle, gender, and genetic polymorphisms [159]. It is noteworthy that LDL cholesterol is the principal plasma carrier of tocopherol. Consequently, vitamin E concentration is influenced by the number of plasma lipids and LDL cholesterol [160].

The bioactivity of vitamin E includes inhibiting oxidative stress, protecting cell membrane, regulating platelet aggregation, and stimulating the host immune defense [161]. Vitamin E promotes membrane repair by inhibiting lipid peroxidation, therefore interfering with phospholipid oxidized generation [162]. According to antioxidant activity, vitamin E also protects lipoproteins and membrane polyunsaturated fatty acids from oxidative damage [163]. By suppressing the function of protein kinase C, vitamin E interferes with platelet aggregation, nitric oxide generation in endothelial cells, superoxide anions expression in neutrophils and macrophages and regulates smooth muscle cell proliferation [164].

**3.11. Vitamin E and Immune Function.** Vitamin E stimulates the cytotoxic activity of NK cells, downregulates the expression of proinflammatory cytokines and PGE2, and thereby indirectly protects T cell function [165]. It has been reported that vitamin E modulates T cell functions including DTH response, the proliferation of lymphocytes, and IL-2 generation by directly promoting membrane integrity and signaling pathways in T cells [166]. Moreover, vitamin E downregulates IL-12 and IL-4 secretion from DCs and T cells, respectively. Furthermore, vitamin E can inhibit the NF- $\kappa$ B pathway indirectly in DCs through the upregulation of Klotho, a membrane protein that mediates calcium transport into the cell [167].

**3.12. The Effect of Vitamin E and C on *H. pylori* Eradication.** An in vivo study investigated the effect of vitamin E



supplementation on *H. pylori*-induced mucosal injury of male Mongolian gerbils and reported that the vitamin E-sufficient or supplemented group demonstrated no gastric ulceration. This study also reported that the enhanced expressions of CD11b/CD18 and keratinocyte-derived chemokine were downregulated by vitamin E administration, thereby inhibiting neutrophil infiltration [168]. Another study on Mongolian gerbils showed a short-term suppression of mucosal protein carbonyls and thiobarbituric acid reactive substances (TBARS) expression by vitamin E supplementation [169]. However, Zhang et al. reported no inhibitory activity for vitamin E on the colonization of *H. pylori* even at the high concentration (4096 mg/mL) using the agar dilution method [170]. This might indicate that vitamin E alone is incapable of suppressing *H. pylori* colonization but can come up with synergic effects in cosupplementation with antibiotic treatment.

The co-supplementation of vitamin E and C exhibits an additive activity because vitamin C can deoxidize vitamin E after the oxidation of vitamin E during deoxidation of ROS, and accordingly, a few pieces of research indicated the benefit of antioxidant intake during *H. pylori* eradication (Table 2) [171–173]. On the contrary, several studies declined the beneficial effect of vitamin C and E administration on *H. pylori* eradication rate [174, 175]. Chuang et al. concluded that vitamin C and E supplementation not only has no inhibitory activity against *H. pylori* but also may reduce the efficiency of metronidazole-based therapy in patients infected with metronidazole-susceptible strains [176]. Interestingly, it has been reported that the mucosal content of  $\alpha$ -tocopherol in the corpus of patients with *H. pylori* infection is lower than in the antrum or duodenum [177]. It is most likely due to the mobilization of antioxidant defenses to the regions of severe inflammation in the stomach [178]. Further large-scale population studies are required to determine the impact of vitamin E and C oral administration on *H. pylori* eradication rate. Moreover, in vitro investigations are needed to elucidate the mechanism of direct interaction between *H. pylori* and these vitamins.

**3.13. Vitamin B.** Vitamin B is composed of eight separate water-soluble important elements including B1 (thiamine), B2 (riboflavin), B3 (niacin), B5 (pantothenic acid), B6 (pyridoxine), B7 (biotin), B9 (folate), and B12 (cobalamin) [184]. Except for vitamin B3, that can be made of tryptophan, none of the B vitamins is produced by the human body and must be acquired from the diet or microbial sources such as gut microbiota [185]. However, the main sources for vitamin B12 are animal foods such as meat, fish, eggs, or dairy products [186].

**3.14. Vitamin B and Immune Function.** B vitamin family is involved in cellular metabolism pathways and immune regulation. Vitamin B6 mediates lymphocyte migration probably by regulating lipid mediator sphingosine 1-phosphate (S1P) which plays a pivotal role in cell trafficking; consequently, the deficiency of vitamin B6 is associated with lymphoid atrophy and lymphocyte reduction [187]. Vitamin

B9 (folate) deficiency is associated with impaired cytotoxicity of NK cells and a substantial reduction in the number of T cells, NK cells, and most of all, B cells [188]. Folate-reduced state downregulates the expression of antiapoptotic Bcl2; therefore, the differentiated regulatory T (Treg) cells from naïve T cells will fail to survive [189]. An in vivo study exhibited that folate deficiency results in thymus and spleen atrophy, reduced proliferation of spleen lymphocytes, and decreased the number of circulating T lymphocytes; however, no effects were observed on the neutrophils [190]. The deficiency of vitamin B12 is related to a significant reduction in the number of lymphocytes, CD8<sup>+</sup>, and CD4<sup>+</sup> as well as the activity of NK cells [191]. Vitamin B12 supplementation in Alzheimer's patients has demonstrated reduced expression of proinflammatory cytokines such as IL-8 and TNF- $\alpha$  and enhanced production of anti-inflammatory cytokine TGF- $\beta$  [192].

**3.15. Vitamin B and *H. pylori* Infection.** One of the main complications of atrophic gastritis is vitamin B12 or cobalamin malabsorption [193]. The inefficacy of individuals to absorb food-bound or protein-bound cobalamin, while typically capable of absorbing free cobalamin, is defined as food-cobalamin malabsorption [194]. Shuval-Sudai and Granot exhibited a link between *H. pylori* infection and the frequency of reduced cobalamin concentration [195]. Acid suppressive therapy and *H. pylori*-induced changes in intragastric pH are most likely the main causes of vitamin B12 malabsorption [194]. Cobalamin malabsorption is common in the elderly due to achlorhydria and hypochlorhydria, bacterial overgrowth, and decreased intrinsic factor synthesis and secretion [193]. It has been proposed that *H. pylori* infection might have a significant role in the reduction of acid production and intrinsic factor secretion and hence develops vitamin B12 insufficiency [196]. Megaloblastic anemia is the typical symptom of vitamin B12 deficiency, yet it occurs only in 50% of vitamin B12-deficient individuals [197].

The link between folate and *H. pylori* infection has been studied only in a few pieces of research. Regarding adults, several researchers have shown an inverse connection between *H. pylori* infection and folate metabolism [13]. A reduction in folate absorption may occur as a result of reduced vitamin C levels in gastric juice and elevated intragastric pH, as is typical in *H. pylori* infection [198]. However, Ackam et al. reported no significant impact on folate concentration in *H. pylori*-infected children [199].

#### **4. *H. pylori* and Minerals**

Despite the presence of a micromolar amount of minerals in the human body, imperceptible alteration in their concentration may lead to significant modification of the host biology. The delicate interaction of minerals with the immune system as well as pathogenic bacteria highlights the importance of mineral homeostasis in preventing *H. pylori*-induced inflammation, as further discussed below (Table 3).

TABLE 2: The effects of vitamin supplementation on *H. pylori* eradication.

Country	Study design	Eradication regimen	Antioxidant supplementation	Confirming <i>H. pylori</i> infection test	Confirming <i>H. pylori</i> eradication Method	ITT eradication		PP eradication		References
						Without antioxidant	With antioxidant	Without antioxidant	With antioxidant	
Taiwan	Randomized controlled trial	Lansoprazole 30 mg bid, amoxicillin 1000 mg bid, metronidazole 500 mg bid, 7 days	(vitamin C 250 mg + vitamin E 200 mg) bid, 7 days and (vitamin C 250 mg + vitamin E 200 mg) qd, 42 days	H, C	H, C, UBT	29/49	22/55	29/45	22/50	[176]
UK	Randomized controlled trial	Metronidazole 400 mg tid, bismuth chelate 120 mg qid, tetracycline 500 mg qid, 14 days	(vitamin C 200 mg + vitamin E 50 mg) bid, 28 days	H, C, RUT	H, C, RUT	17/30	19/29	17/25	19/24	[179]
Iran	Randomized controlled trial	Amoxicillin 1000 mg bid, omeprazole 20 mg bid, clarithromycin (250 mg in antioxidants group and 500 mg in without antioxidants group) bid, 14 days	Vitamin C 250 mg bid, 14 days	H, RUT	UBT	89/100	99/114	89/100	99/114	[180]
Turkey	Randomized controlled trial	Amoxicillin 1000 mg bid, clarithromycin 500 mg bid, bismuth subcitrate 300 mg qid, lansoprazole 30 mg bid, 14 days	(vitamin C 500 mg + vitamin E 200 mg) bid, 30 days	H, RUT	UBT, SAT	48/80	73/80	48/75	73/78	[172]
Iran	Randomized controlled trial	Amoxicillin 500 mg bid, metronidazole 500 mg bid, bismuth 240 mg bid, omeprazole 20 mg bid, 14 days	Vitamin C 500 mg qd, 14 days	RUT	UBT	68/140	110/141	79/140	117/150	[181]
Turkey	Randomized controlled trial	Amoxicillin 1000 mg bid, clarithromycin 500 mg bid, lansoprazole 30 mg bid, 14 days	(vitamin C 500 mg + vitamin E 200 mg) bid, 30 days	H, RUT	UBT	17/40	51/80	17/38	51/77	[182]
Turkey	Randomized controlled trial	Amoxicillin 1000 mg bid, Clarithromycin 500 mg bid, Lansoprazole 30 mg bid, 14 days	(vitamin C 500 mg + vitamin E 200 mg) bid, 30 days	H, RUT	UBT	18/40	132/160	18/38	132/157	[171]
Egypt	Randomized controlled trial	Amoxicillin 1000 mg bid, clarithromycin 500 mg bid, esomeprazole 20 mg bid, 14 days	Vitamin C 500 mg bid, 28 days	ME-NBI, H, SAT	SAT	31/50	34/50	31/44	34/46	[183]

qd, once a day; bid, twice a day; tid, three times a day; qid, four times a day; H, histopathologic examination; UBT, urea breath test; RUT, rapid urease test; SAT, stool antigen test; C, culture; ME-NBI, magnifying endoscopy with narrow band imaging; ITT, intention-to-treat; PP, per protocol.

**4.1. Iron.** Despite the toxic properties of iron, it is a biologically vital element, contributing to hemoglobin production and heme and iron-sulfur cluster generation, and therefore regulates respiration, nucleic acid repair and replication, metabolic reactions, and immune response [224]. The regulation of iron concentration relies on hepcidin, ferroportin, and hypoxia-inducible factor-2 (HIF2). HIF2 regulates the production of proteins involved in iron absorption, while hepcidin, a liver-derived hormone, blocks ferroportin to inhibit iron absorption, storage, and recycling in duodenal enterocytes, hepatocytes, and reticuloendothelial macrophages, respectively [225]. In addition to general iron homeostasis, nutritional immunity as a dynamic mechanism allows the host to respond to pathogenic attacks and prevents bacterial growth by restricting bacterial access and intracellular availability to iron [226].

**4.2. Iron and Immune Function.** Oxygen burst by NADPH oxidase is a defensive response of neutrophils. By forming hydroxyl radicals in the interaction with hydrogen peroxide, iron is involved in the antimicrobial activity of neutrophils [200]. Polymorphonuclear leukocytes and monocytes release myeloperoxidase (MPO), an antimicrobial hemoprotein that requires the  $\text{Fe}^{3+}/\text{Fe}^{2+}$  redox state for its activity [201]. Concerning T cells, iron changes the equilibrium between Th1 and Th2 cells towards Th2 and thereby increases the expression of IL-4 and inhibits the secretion of IFN- $\gamma$  [202]. Iron supplementation, depending on the amount and form of iron, can trigger certain cellular events such as the polarization of macrophages and proinflammatory and anti-inflammatory cytokine secretion [207].

**4.3. Iron and *H. pylori* Infection.** Iron deficiency is a major marker of *H. pylori* infection, and thereby, multiple pieces of research attempted to elucidate this relationship. Although several studies indicated the correlation between *H. pylori* infection and iron deficiency or iron-dependent anemia, regardless of the presence or absence of peptic ulcer [228, 229], Savio et al. reported no relation regarding *H. pylori* infection in elder adults and unexplained iron insufficiency or anemia [230]. However, the origin and mechanisms underlying this possible connection are yet to be fully understood. It is suggested that owing to the higher iron requirement in *H. pylori* than other pathogens, competing for iron dietary leads to iron malabsorption in the host [231]. Moreover, the progression of *H. pylori*-induced infection can cause gastritis or duodenitis which might further result in gastrointestinal blood loss and anemia [203]. In addition, *H. pylori* induces hepcidin expression and thereby decreases iron secretion from macrophages [204]. The reduction in free iron elements can lead to cobalamin malabsorption due to the decreased iron-dependent cobalamin transporters [203].

**4.4. Zinc.** Zinc homeostasis mainly relies on intestinal absorption which occurs through zinc transporters on the apical and basolateral membrane of enterocytes and further by cellular zinc-binding protein metallothionein [232]. Calprotectin, a member of the S100A protein family, regu-

lates the zinc concentration at the host-pathogen interface [233]. Insufficiency or overload of zinc level has an impact on growth, morphogenesis, immune response, neurosensory, and endocrine activity [234]. At the cellular level, zinc plays a pivotal role in proliferation, differentiation, and apoptosis [235].

**4.5. Zinc and Immune Function.** Zinc is an essential micronutrient to maintain the gut barrier by regeneration of intestinal epithelium, preserving the function and structure of membrane barrier and regulating the proliferation of immune cells [205]. The granulocyte recruitment, monocytes adhesion to epithelial cells, and ROS generation are dependent on zinc concentration. It has also been revealed that zinc deficiency is associated with a reduction in the number of granulocytes and NK cells and the phagocytic capacity of macrophages [206]. Low serum level of zinc increases the production of proinflammatory cytokines such as IL-1 $\beta$ , IL-6, and TNF- $\alpha$ , shifts the balance between Th1 and Th2 toward Th2, causes thymus atrophy, and reduces lymphopoiesis and antibody expression of T and B lymphocytes [207, 208].

**4.6. Zinc and *H. pylori* Infection.** *H. pylori* requires zinc to induce inflammatory activity including CagA translocation, Cag-T4SS pilus formation, NF- $\kappa$ B activation, and consequently IL-8 expression [209]. To disrupt the activity of *H. pylori* virulence factors, the host antibacterial proteins including calprotectin (S100A8/A9 heterodimer) or calgranulin C (S100A12 homodimer) inhibit the access of pathogen to zinc elements [210]. Furthermore, Sempértegui et al. reported a negative correlation between *H. pylori*-induced gastric inflammation and gastric mucosa zinc concentration [236]. Interestingly, that innate immune defense exploits a high concentration of zinc and copper in the macrophage to eliminate the trapped bacteria. However, *H. pylori* evolved three zinc transport systems including CadA, CrdB-CzcAB complex, and CznABC system to survive high levels of zinc [210]. As this element plays a variety of roles in both *H. pylori* and the host immune system, further studies are required to elucidate the interplay between zinc bioavailability and *H. pylori*-induced inflammation. Moreover, the fate of trapped bacteria in the macrophage during the increased concentration of zinc needs to be further investigated.

**4.7. Selenium.** Selenium is a cofactor of glutathione peroxidase (GPx), which is a protective enzyme for cell membranes against oxidative damage [237]. The biologic effects of selenium are primarily mediated by the activity of selenoproteins that take part in a variety of cellular pathways, such as antioxidant defense to reduce oxidative stress and DNA damage, induction of phase II conjugating enzymes for carcinogen detoxification, and reduction of DNA adduct generation, prevention of cell proliferation, stimulation of DNA repair and apoptosis via the p53 tumor suppressor gene, and inactivation of proliferating cells [238].

**4.8. Selenium and Immune Function.** Selenium intake is involved in immune cell activation, differentiation, and

TABLE 3: The influence of minerals bioavailability on the host and *H. pylori* pathogenicity.

Mineral	Functions	Deficiency	Interaction with <i>H. pylori</i>
Iron	Involved in anti-microbial activity of neutrophils, polymorphonuclear leukocytes and monocytes [200, 201]; Changes the equilibrium between Th1 and Th2 cells towards Th2 [202]	Cobalamin malabsorption [203]	<i>H. Pylori</i> -induced gastric bleeding leads to anemia [203]; <i>H. Pylori</i> -induced hepcidin expression reduces iron secretion from macrophages [204]
Zinc	Maintains gut barrier [205]; Involved in granulocyte recruitment [125]; Involved in monocytes adhesion to epithelial cells [125]; Involved in ROS generation [125]	Reduces the number of granulocytes and NK cells [206]; Reduces macrophages activity [206]; Increases pro-inflammatory cytokines production [207]; Shifts the balance between Th1 and Th2 toward Th2 [207, 208]; Reduces lymphopoiesis and antibody expression of T and B lymphocytes [207, 208]	Required for <i>cagPAI</i> functionality [209]; Calprotectin or calgranulin C restricts <i>H. pylori</i> access to zinc [210]; High concentrations of zinc eliminate bacteria [210]
Selenium	Preserves the equilibrium between reduced and oxidized molecules within cells [211]; Skews the differentiation of CD4+ T cells toward Th1 [212, 213]; Decreases intra-abdominal adhesion formation [214]	Reduces the activation, maturation, and anti-microbial activity of T cells [212, 213]; Reduces the expression of B cell-dependent antibodies [212, 213]	Contradictory results
Copper	Involved in leukocyte proliferation and maturation [215]	Impairs the activity of macrophages, neutrophils, and monocytes [215]; Decreases the number of neutrophils [215]	No correlation with <i>H. pylori</i> eradication [216]
Magnesium	Decreases macrophage activation [217]; Downregulates cytokines expression in activated macrophages [217]; Impedes the activation of NF- $\kappa$ B [217]	Increases apoptosis, oxidative stress, and production of pro-inflammatory cytokines [218]; Decreases the number of CD8+ T cells [219]	Involved in phosphonate and phenyl phosphonate degradation in <i>H. pylori</i> [220]
Nickel	Potentially suppresses immune response [221]; Increases IFN- $\gamma$ secretion from NK cells [222]	Nickel-free diet may improve <i>H. pylori</i> eradication [223]	Required for Ni-Fe-hydrogenase and urease [223]

proliferation. Specific selenoproteins also play a major part to preserve the equilibrium between reduced and oxidized molecules within the host cells [211]. It is apparent that selenium deficiency not only reduces the activation, maturation, and antimicrobial activity of T cells but also downregulates the expression of B cell-dependent antibodies. On the other hand, higher selenium intake skews the differentiation of CD4<sup>+</sup> T cells toward Th1 by stimulating TCR signaling and consequently increases the production of proinflammatory cytokines [212, 213]. Selenium supplementation might decrease intra-abdominal adhesion formation and this is a possible mechanism by which selenium intake moderates inflammation [214].

**4.9. Selenium and *H. pylori* Infection.** Few studies that investigated the correlation between *H. pylori* and selenium serum concentration exhibited contradictory results. Camargo et al. reported that a high-risk population for gastric cancer demonstrated lower plasma selenium levels than low-risk areas [239]. However, Öztürk et al. demonstrated no substantial differences in serum selenium levels between *H. pylori*-infected and noninfected children [240]. On the contrary, it is suggested that selenium accumulates

in gastric tissue during *H. pylori* infection owing to the excessive ROS production [241].

**4.10. Copper.** Copper is a vital nutritional element of human physiology, which is required as a catalytic cofactor in several enzymatic processes, such as an allosteric enzyme component and an antioxidant which plays a key role in the oxidant defense system [242]. In the adult human body, the copper content is predicted to be between 50 and 120 mg. It is presented in large concentrations in the liver and brain, and to a lesser extent in the kidneys, heart, and pancreas. Microcytic anemia, leukopenia, osteoporosis, new subperiosteal bone growth, and epiphysis fibrosis can all be developed from copper deficiency [243].

**4.11. Copper, Immunity, and *H. pylori* Infection.** Copper is involved in leukocyte proliferation and maturation; thereby, its deficiency decreases the number of neutrophils and impairs the activity of macrophages, neutrophils, and monocytes [215]. In vivo studies have demonstrated that copper diet levels impact the susceptibility of the host to pathogenic infection, and thereby sensitize the animal models to



infection, extend the infection duration, and increase the mortality rate [244].

According to Janjetic et al., serum copper levels in children might be linked to gastric *H. pylori* infection; however, further studies are required to confirm this correlation [245]. Regarding adults, studies indicated no significant difference in serum copper levels between *H. pylori*-infected and noninfected individuals. Furthermore, no substantial difference in serum copper concentration is detected concerning the successful eradication of *H. pylori*. Wu et al. reported that although triple therapy significantly reduces the selenium serum levels, copper levels remained the same after *H. pylori* eradication [216].

**4.12. Magnesium.** Magnesium ( $Mg^{2+}$ ) is a cofactor of numerous enzymes engaged in critical metabolic processes required for bacterial survival. Pathogenic bacteria express specific  $Mg^{2+}$  absorption mechanisms to circumvent the  $Mg^{2+}$  restriction within the human host [246]. On the other hand, in the human body,  $Mg^{2+}$  is mainly absorbed in the small intestine through paracellular transport and membrane transporters. Due to the poor expression of claudins in the small intestine, paracellular transport is the most common mechanism for magnesium transportation [247].

**4.13. Magnesium, Immunity, and *H. pylori* Infection.** It is long known that the antioxidant and anti-inflammatory activities of magnesium support the immune system against several diseases [248].  $Mg^{2+}$  decreases macrophage activation, downregulates cytokine expression in activated macrophages at the mRNA level, and impedes the NF- $\kappa$ B activation [217]. Low serum levels of magnesium increase apoptosis, oxidative stress, and proinflammatory cytokine production [218]. Magnesium deficiency also decreases the number of  $CD8^+$  T cells and possibly leads to reduced IFN- $\gamma$  concentration [219].

In *H. pylori*, phosphate metabolism, particularly the catabolism of phosphonates, is strongly reliant on  $Mg^{2+}$ , which can serve as a significant supply of phosphorous. *H. pylori* may degrade the phosphonate and phenyl phosphonate and use them as a single supply of phosphate. This catabolism was demonstrated to be increased by exogenous  $MgCl_2$  and inhibited by the ethylenediaminetetraacetic acid (EDTA) [220].

**4.14. Nickel and Immune Function.** There are contradictory results regarding the immunomodulation capacity of nickel, yet solid evidence indicates that nickel potentially suppresses the host immune response [221]. The exposure of immune cells to a low concentration of nickel can influence the normal activity of the immune system [249]. Splenic NK cells were demonstrated to express IFN- $\gamma$  as a direct or indirect response to nickel detection in the cell culture system. Substantial reduction in the presence of nickel-reactive cells following the depletion of NK cells in an animal model was further reported to confirm the in vitro results [222]. The involvement of  $CD25^+$  Treg in the activation of nickel-specific T cells is suggested to promote nickel toler-

ance and potentially prevent the development of allergic contact dermatitis [250].

**4.15. Nickel and *H. pylori* Infection.** In addition to zinc and iron, *H. pylori* requires the nickel transition to survive in the host and promotes its pathogenic activity. By leveraging nickel-containing metalloenzymes such as Ni-Fe-hydrogenase and urease, *H. pylori* can survive the acidic condition of the human stomach [223]. Urease, as one of the most prevalent enzymes in the *H. pylori* proteome, consists of 24 nickel atoms to generate ammonia and bicarbonate from urea [251]. However, excessive concentration of nickel in the bacterial cell causes mismetallation of cellular enzymes, which can further impair its physiological function [252]. *H. pylori* is likely to come into contact with micromolar amounts of transition metals such as nickel from the host food, which can alter nickel homeostasis as well as the activity of hydrogenase and urease [253]. As a result, *H. pylori* can extremely control both the nickel import and export functions in its cellular nickel economy [254]. Nickel is transported into the bacterial cell by a NixA permease [255] and the FrpB4 outer membrane protein in a TonB-dependent manner [256]. A recent study demonstrated that SlyD, a protein combining peptidyl-prolyl isomerase (PPIase), chaperone, and metal-binding properties, acts as the gatekeeper of nickel import by regulating the function of Niu permease [257]. The promiscuous CznABC transporter facilitates nickel efflux and thereby enhances nickel resistance in *H. pylori* [253]. Campanale et al. exhibited that keeping patients on a nickel-free diet improves *H. pylori* treatment, suggesting the importance of nickel in *H. pylori* pathogenesis [223].

## 5. Concluding Remarks

In this review, we discussed the effects of vitamins A, D, C, E, B6, B9, and B12, as well as the key minerals such as zinc, iron, copper, nickel, and selenium on immune function and their involvement in *H. pylori* infection and eradication. The antioxidant activity of vitamins can reduce oxidative stress and further suppress *H. pylori*-induced inflammation. Moreover, in vitro studies demonstrated promising anti-*H. pylori* mechanisms for vitamin administration in a dose-dependent manner. On the other hand, several researchers reported an inverse relation between *H. pylori* infection score and vitamin concentration in the gastric juice. Furthermore, only a few studies demonstrated a negative impact of vitamin administration on *H. pylori* treatment, while other papers exhibited a substantial or comparable advantage. However, further studies are needed to investigate a large-scale population of infected individuals and elucidate the impact of vitamin supplementation on *H. pylori* eradication rate and side effects.

On the contrary, certain minerals are involved in *H. pylori* pathogenesis as well as the host immune response. The delicate interplay between minerals, immune system, and *H. pylori* infection remains to be fully elucidated. The contradictory reports regarding alteration in the host serum levels of minerals after *H. pylori* treatment require further

examination. Additionally, *in vitro* studies are of great significance to clarify the interaction between mineral concentrations, *H. pylori* pathogenesis, and the host cellular pathways.

### Conflicts of Interest

None declared.

### Authors' Contributions

ANR, MA, SJ, and AY contributed significantly to the literature review and wrote the draft of the manuscript. ANR and AY designed and illustrated the figure. AY worked on the concept and design of the study and interpreted the collected information. AS, HAA, and MRZ provided clinical advice and guidance for the improvement of the manuscript. AY critically revised the final version of the manuscript. All authors have seen and approved the final version of the manuscript and the author list.

### Acknowledgments

This study was financially supported by a research grant (no. RIGLD 1128, IR.SBMU.RIGLD.REC.1399.046) from the Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran. We sincerely express our gratitude to all the members of the Foodborne and Waterborne Diseases Research Center at the Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

### References

- [1] S. Ansari and Y. Yamaoka, "Survival of *Helicobacter pylori* in gastric acidic territory," *Helicobacter*, vol. 22, no. 4, 2017.
- [2] G. Khoder, J. S. Muhammad, I. Mahmoud, S. S. M. Soliman, and C. Burucoa, "Prevalence of *Helicobacter pylori* and its associated factors among healthy asymptomatic residents in the United Arab Emirates," *Pathogens*, vol. 8, no. 2, 2019.
- [3] J. W. T. Toh and R. B. Wilson, "Pathways of gastric carcinogenesis, *Helicobacter pylori* virulence and interactions with antioxidant systems, vitamin C and phytochemicals," *International Journal of Molecular Sciences*, vol. 21, no. 17, 2020.
- [4] N. Farzi, A. Yadegar, H. A. Aghdaei, Y. Yamaoka, and M. R. Zali, "Genetic diversity and functional analysis of oipA gene in association with other virulence factors among *Helicobacter pylori* isolates from Iranian patients with different gastric diseases," *Infection, Genetics and Evolution*, vol. 60, pp. 26–34, 2018.
- [5] A. Yadegar, A. Mohabati Mobarez, and M. R. Zali, "Genetic diversity and amino acid sequence polymorphism in *Helicobacter pylori* Cag L hypervariable motif and its association with virulence markers and gastroduodenal diseases," *Cancer Medicine*, vol. 8, no. 4, pp. 1619–1632, 2019.
- [6] N. Farzi, A. Yadegar, A. Sadeghi et al., "High prevalence of antibiotic resistance in Iranian *Helicobacter pylori* isolates: importance of functional and mutational analysis of resistance genes and virulence genotyping," *Journal of Clinical Medicine*, vol. 8, no. 11, 2019.
- [7] E. A. Marcus, G. Sachs, and D. R. Scott, "Eradication of *Helicobacter pylori* infection," *Current Gastroenterology Reports*, vol. 18, no. 7, p. 33, 2016.
- [8] S. Suzuki, T. Gotoda, C. Kusano et al., "Seven-day vonoprazan and low-dose amoxicillin dual therapy as first-line *Helicobacter pylori* treatment: a multicentre randomised trial in Japan," *Gut*, vol. 69, no. 6, pp. 1019–1026, 2020.
- [9] J. Yuan, Q. He, L. H. Nguyen et al., "Regular use of proton pump inhibitors and risk of type 2 diabetes: results from three prospective cohort studies," *Gut*, vol. 70, no. 6, pp. 1070–1077, 2021.
- [10] J. Kobayashi, H. Uchida, and J. Ito, "Long-term proton pump inhibitor use after *Helicobacter pylori* eradication may create a gastric environment for N-nitrosamine formation and gastric cancer development," *Gut*, vol. 68, no. 6, p. 1131, 2019.
- [11] H. L. Waldum and R. Fossmark, "Proton pump inhibitors and gastric cancer: a long expected side effect finally reported also in man," *Gut*, vol. 67, no. 1, pp. 199–200, 2018.
- [12] D. Y. Graham and L. Fischbach, "*Helicobacter pylori* treatment in the era of increasing antibiotic resistance," *Gut*, vol. 59, no. 8, pp. 1143–1153, 2010.
- [13] F. Franceschi, T. Annalisa, D. R. Teresa et al., "Role of *Helicobacter pylori* infection on nutrition and metabolism," *World Journal of Gastroenterology*, vol. 20, no. 36, article 12809, 2014.
- [14] Y. B. Yang-Ou, Y. Hu, Y. Zhu, and N. H. Lu, "The effect of antioxidants on *Helicobacter pylori* eradication: a systematic review with meta-analysis," *Helicobacter*, vol. 23, no. 6, article e12535, 2018.
- [15] J. Holmgren and C. Czerkinsky, "Mucosal immunity and vaccines," *Nature Medicine*, vol. 11, Supplement 4, pp. S45–S53, 2005.
- [16] D. Ribet and P. Cossart, "How bacterial pathogens colonize their hosts and invade deeper tissues," *Microbes and Infection*, vol. 17, no. 3, pp. 173–183, 2015.
- [17] U. M. Morbe, P. B. Jorgensen, T. M. Fenton et al., "Human gut-associated lymphoid tissues (GALT); diversity, structure, and function," *Mucosal Immunology*, vol. 14, no. 4, pp. 793–802, 2021.
- [18] A. Cerutti, K. Chen, and A. Chorny, "Immunoglobulin responses at the mucosal interface," *Annual Review of Immunology*, vol. 29, pp. 273–293, 2011.
- [19] J. G. Fox and T. C. Wang, "Inflammation, atrophy, and gastric cancer," *The Journal of Clinical Investigation*, vol. 117, no. 1, pp. 60–69, 2007.
- [20] D. Bravo, A. Hoare, C. Soto, M. A. Valenzuela, and A. F. Quest, "*Helicobacter pylori* in human health and disease: mechanisms for local gastric and systemic effects," *World Journal of Gastroenterology*, vol. 24, no. 28, pp. 3071–3089, 2018.
- [21] A. Ieni, V. Barresi, L. Rigoli, F. Fedele, G. Tuccari, and R. A. Caruso, "Morphological and cellular features of innate immune reaction in *Helicobacter pylori* gastritis: a brief review," *International Journal of Molecular Sciences*, vol. 17, no. 1, 2016.
- [22] H. W. Fu, "*Helicobacter pylori* neutrophil-activating protein: from molecular pathogenesis to clinical applications," *World Journal of Gastroenterology: WJG*, vol. 20, no. 18, pp. 5294–5301, 2014.
- [23] H. Nagura, H. Ohtani, H. Sasano, and T. Matsumoto, "The immuno-inflammatory mechanism for tissue injury in

- inflammatory bowel disease and *Helicobacter pylori*-infected chronic active gastritis. Roles of the mucosal immune system," *Digestion*, vol. 63, Supplement 1, pp. 12–21, 2001.
- [24] A. A. Birukova, T. Zagranichnaya, P. Fu et al., "Prostaglandins PGE (2) and PGI (2) promote endothelial barrier enhancement via PKA- and Epac 1/Rap 1-dependent Rac activation," *Experimental Cell Research*, vol. 313, no. 11, pp. 2504–2520, 2007.
- [25] C. C. Yost, A. S. Weyrich, and G. A. Zimmerman, "The platelet activating factor (PAF) signaling cascade in systemic inflammatory responses," *Biochimie*, vol. 92, no. 6, pp. 692–697, 2010.
- [26] P. Bouti, S. D. S. Webbers, S. C. Fagerholm et al., " $\beta$ 2 integrin signaling cascade in neutrophils: more than a single function," *Frontiers in Immunology*, vol. 11, 2020.
- [27] B. S. Qazi, K. Tang, and A. Qazi, "Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis," *International Journal of Inflammation*, vol. 2011, Article ID 908468, 13 pages, 2011.
- [28] M. Nita and A. Grzybowski, "The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults," *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 3164734, 23 pages, 2016.
- [29] A. V. Snezhkina, A. V. Kudryavtseva, O. L. Kardymon et al., "ROS generation and antioxidant defense systems in normal and malignant cells," *Oxidative Medicine and Cellular Longevity*, vol. 2019, Article ID 6175804, 17 pages, 2019.
- [30] L. D. Butcher, G. den Hartog, P. B. Ernst, and S. E. Crowe, "Oxidative stress resulting from *Helicobacter pylori* infection contributes to gastric carcinogenesis," *Cellular and Molecular Gastroenterology and Hepatology*, vol. 3, no. 3, pp. 316–322, 2017.
- [31] A. Stent, A. L. Every, and P. Sutton, "*Helicobacter pylori* defense against oxidative attack," *American Journal of Physiology. Gastrointestinal and Liver Physiology*, vol. 302, no. 6, pp. G579–G587, 2012.
- [32] L. Alvarez-Arellano and C. Maldonado-Bernal, "*Helicobacter pylori* and neurological diseases: married by the laws of inflammation," *World Journal of Gastrointestinal Pathophysiology*, vol. 5, no. 4, pp. 400–404, 2014.
- [33] G. S. Selders, A. E. Fetz, M. Z. Radic, and G. L. Bowlin, "An overview of the role of neutrophils in innate immunity, inflammation and host-biomaterial integration," *Regenerative Biomaterials*, vol. 4, no. 1, pp. 55–68, 2017.
- [34] S. Yoshida, A. Yoshida, H. Matsui, Y. Takada, and T. Ishibashi, "Involvement of macrophage chemotactic protein-1 and interleukin-1 $\beta$  during inflammatory but not basic fibroblast growth factor-dependent neovascularization in the mouse cornea," *Laboratory Investigation*, vol. 83, no. 7, pp. 927–938, 2003.
- [35] L. Virag, R. I. Jaen, Z. Regdon, L. Bosca, and P. Prieto, "Self-defense of macrophages against oxidative injury: fighting for their own survival," *Redox Biology*, vol. 26, 2019.
- [36] G. I. Perez-Perez, V. L. Shepherd, J. D. Morrow, and M. J. Blaser, "Activation of human THP-1 cells and rat bone marrow-derived macrophages by *Helicobacter pylori* lipopolysaccharide," *Infection and Immunity*, vol. 63, no. 4, pp. 1183–1187, 1995.
- [37] D. Y. Lu, C. H. Tang, C. H. Chang et al., "*Helicobacter pylori* attenuates lipopolysaccharide-induced nitric oxide production by murine macrophages," *Innate Immunity*, vol. 18, no. 3, pp. 406–417, 2012.
- [38] O. Handa, Y. Naito, and T. Yoshikawa, "*Helicobacter pylori*: a ROS-inducing bacterial species in the stomach," *Inflammation Research*, vol. 59, no. 12, pp. 997–1003, 2010.
- [39] D. Tsikas, E. Hanff, and G. Brunner, "*Helicobacter pylori*, its urease and carbonic anhydrases, and macrophage nitric oxide synthase," *Trends in Microbiology*, vol. 25, no. 8, pp. 601–602, 2017.
- [40] N. R. Salama, M. L. Hartung, and A. Muller, "Life in the human stomach: persistence strategies of the bacterial pathogen *Helicobacter pylori*," *Nature Reviews Microbiology*, vol. 11, no. 6, pp. 385–399, 2013.
- [41] S. K. Lee and C. Josenhans, "*Helicobacter pylori* and the innate immune system," *International Journal of Medical Microbiology*, vol. 295, no. 5, pp. 325–334, 2005.
- [42] A. Muller, M. Oertli, and I. C. Arnold, "*H. pylori* exploits and manipulates innate and adaptive immune cell signaling pathways to establish persistent infection," *Cell Communication and Signaling: CCS*, vol. 9, no. 1, 2011.
- [43] T. Kawasaki and T. Kawai, "Toll-like receptor signaling pathways," *Frontiers in Immunology*, vol. 5, p. 461, 2014.
- [44] J. P. Mitchell and R. J. Carmody, "NF-kappa B and the transcriptional control of inflammation," *International Review of Cell and Molecular Biology*, vol. 335, pp. 41–84, 2018.
- [45] S. Trop-Steinberg and Y. Azar, "AP-1 expression and its clinical relevance in immune disorders and cancer," *The American Journal of the Medical Sciences*, vol. 353, no. 5, pp. 474–483, 2017.
- [46] C. Peng, Y. Ouyang, N. Lu, and N. Li, "The NF-kappa B signaling pathway, the microbiota, and gastrointestinal tumorigenesis: recent advances," *Frontiers in Immunology*, vol. 11, p. 1387, 2020.
- [47] O. Sokolova and M. Naumann, "NF-kappa B signaling in gastric cancer," *Toxins*, vol. 9, no. 4, 2017.
- [48] D. Doohan, Y. A. A. Rezkitha, L. A. Waskito, Y. Yamaoka, and M. Miftahussurur, "*Helicobacter pylori* BabA-SabA key roles in the adherence phase: the synergic mechanism for successful colonization and disease development," *Toxins*, vol. 13, no. 7, p. 485, 2021.
- [49] N. Ito, H. Tsujimoto, H. Ueno, Q. Xie, and N. Shinomiya, "*Helicobacter pylori*-mediated immunity and signaling transduction in gastric cancer," *Journal of Clinical Medicine*, vol. 9, no. 11, 2020.
- [50] R. Chaturvedi, M. Asim, M. B. Piazuelo et al., "Activation of EGFR and ERBB2 by *Helicobacter pylori* results in survival of gastric epithelial cells with DNA damage," *Gastroenterology*, vol. 146, no. 7, pp. 1739–1751, 2014.
- [51] A. Lamb and L. F. Chen, "Role of the *Helicobacter pylori*-induced inflammatory response in the development of gastric cancer," *Journal of Cellular Biochemistry*, vol. 114, no. 3, pp. 491–497, 2013.
- [52] S. O. Cho, J. W. Lim, K. H. Kim, and H. Kim, "Involvement of Ras and AP-1 in *Helicobacter pylori*-induced expression of COX-2 and iNOS in gastric epithelial AGS cells," *Digestive Diseases and Sciences*, vol. 55, no. 4, pp. 988–996, 2010.
- [53] A. C. Cadamuro, A. F. Rossi, N. M. Maniezzo, and A. E. Silva, "*Helicobacter pylori* infection: host immune response,



- implications on gene expression and micro RNAs," *World Journal of Gastroenterology*, vol. 20, no. 6, pp. 1424–1437, 2014.
- [54] E. Price, "Could the severity of COVID-19 be increased by low gastric acidity?," *Critical Care*, vol. 24, no. 1, p. 456, 2020.
- [55] M. Valenzuela-Valderrama, P. Cerda-Opazo, S. Backert et al., "The *Helicobacter pylori* urease virulence factor is required for the induction of hypoxia-induced factor-1 $\alpha$  in gastric cells," *Cancers*, vol. 11, no. 6, 2019.
- [56] T. D. Schoep, A. Fulurija, F. Good et al., "Surface properties of *Helicobacter pylori* urease complex are essential for persistence," *PLoS One*, vol. 5, no. 11, article e15042, 2010.
- [57] R. M. Peek Jr., C. Fiske, and K. T. Wilson, "Role of innate immunity in *Helicobacter pylori*-induced gastric malignancy," *Physiological Reviews*, vol. 90, no. 3, pp. 831–858, 2010.
- [58] J. Viala, C. Chaput, I. G. Boneca et al., "Nod 1 responds to peptidoglycan delivered by the *Helicobacter pylori* cag pathogenicity island," *Nature Immunology*, vol. 5, no. 11, pp. 1166–1174, 2004.
- [59] W. Fischer, B. Gebert, and R. Haas, "Novel activities of the *Helicobacter pylori* vacuolating cytotoxin: from epithelial cells towards the immune system," *International Journal of Medical Microbiology*, vol. 293, no. 7–8, pp. 539–547, 2004.
- [60] M. S. Sundrud, V. J. Torres, D. Unutmaz, and T. L. Cover, "Inhibition of primary human T cell proliferation by *Helicobacter pylori* vacuolating toxin (Vac A) is independent of Vac A effects on IL-2 secretion," *Proceedings of the National Academy of Sciences*, vol. 101, no. 20, pp. 7727–7732, 2004.
- [61] S. W. Chang and H. C. Lee, "Vitamin D and health - the missing vitamin in humans," *Pediatrics and Neonatology*, vol. 60, no. 3, pp. 237–244, 2019.
- [62] A. Schmid and B. Walther, "Natural vitamin D content in animal products," *Advances in Nutrition*, vol. 4, no. 4, pp. 453–462, 2013.
- [63] L. Tripkovic, H. Lambert, K. Hart et al., "Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis," *The American Journal of Clinical Nutrition*, vol. 95, no. 6, pp. 1357–1364, 2012.
- [64] D. D. Bikle, "Vitamin D metabolism, mechanism of action, and clinical applications," *Chemistry & Biology*, vol. 21, no. 3, pp. 319–329, 2014.
- [65] M. Di Rosa, M. Malaguarnera, F. Nicoletti, and L. Malaguarnera, "Vitamin D3: a helpful immuno-modulator," *Immunology*, vol. 134, no. 2, pp. 123–139, 2011.
- [66] M. Lu, B. V. Taylor, and H. Körner, "Genomic effects of the vitamin D receptor: potentially the link between vitamin D, immune cells, and multiple sclerosis," *Frontiers in Immunology*, vol. 9, p. 477, 2018.
- [67] C. S. Hii and A. Ferrante, "The non-genomic actions of vitamin D," *Nutrients*, vol. 8, no. 3, p. 135, 2016.
- [68] S. Christakos, S. Li, J. De La Cruz et al., "Vitamin D and the intestine: review and update," *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 196, article 105501, Article ID 10.1016/j.jsbmb.2019.105501, 2020.
- [69] S. Christakos, "Mechanism of action of 1, 25-dihydroxyvitamin D3 on intestinal calcium absorption," *Reviews in Endocrine & Metabolic Disorders*, vol. 13, no. 1, pp. 39–44, 2012.
- [70] J. Blaine, M. Chonchol, and M. Levi, "Renal control of calcium, phosphate, and magnesium homeostasis," *Clinical Journal of the American Society of Nephrology*, vol. 10, no. 7, pp. 1257–1272, 2015.
- [71] D. Bikle, "Nonclassic actions of vitamin D," *The Journal of Clinical Endocrinology & Metabolism*, vol. 94, no. 1, pp. 26–34, 2009.
- [72] I. L. Tourkova, L. Liu, N. Sutjarit et al., "Adrenocorticotropic hormone and 1, 25-dihydroxyvitamin D3 enhance human osteogenesis in vitro by synergistically accelerating the expression of bone-specific genes," *Laboratory Investigation*, vol. 97, no. 9, pp. 1072–1083, 2017.
- [73] A. F. Gombart, A. Pierre, and S. Maggini, "A review of micronutrients and the immune system-working in harmony to reduce the risk of infection," *Nutrients*, vol. 12, no. 1, 2020.
- [74] G. Wang, "Human antimicrobial peptides and proteins," *Pharmaceuticals*, vol. 7, no. 5, pp. 545–594, 2014.
- [75] R. Pero, L. Coretti, E. Nigro et al., "Beta-defensins in the fight against *Helicobacter pylori*," *Molecules*, vol. 22, no. 3, p. 424, 2017.
- [76] L. Di Renzo, P. Gualtieri, F. Pivari et al., "COVID-19: is there a role for immunonutrition in obese patient?," *Journal of Translational Medicine*, vol. 18, no. 1, p. 415, 2020.
- [77] B. Prietl, G. Treiber, T. R. Pieber, and K. Amrein, "Vitamin D and immune function," *Nutrients*, vol. 5, no. 7, pp. 2502–2521, 2013.
- [78] A. Chaari, G. Bendriss, D. Zakaria, and C. McVeigh, "Importance of dietary changes during the coronavirus pandemic: how to upgrade your immune response," *Frontiers in Public Health*, vol. 8, p. 476, 2020.
- [79] W. Liu, L. Zhang, H. J. Xu et al., "The anti-inflammatory effects of vitamin D in tumorigenesis," *International Journal of Molecular Sciences*, vol. 19, no. 9, 2018.
- [80] Y. G. Zhang, S. Wu, R. Lu et al., "Tight junction CLDN2 gene is a direct target of the vitamin D receptor," *Scientific Reports*, vol. 5, article 10642, 2015.
- [81] M. Mihajlovic, M. Fedecostante, M. J. Oost et al., "Role of vitamin D in maintaining renal epithelial barrier function in uremic conditions," *International Journal of Molecular Sciences*, vol. 18, no. 12, 2017.
- [82] A. Gurlek, M. R. Pittelkow, and R. Kumar, "Modulation of growth factor/cytokine synthesis and signaling by 1 $\alpha$ ,25-dihydroxyvitamin D (3): implications in cell growth and differentiation," *Endocrine Reviews*, vol. 23, no. 6, pp. 763–786, 2002.
- [83] N. Dauletbaev, K. Herscovitch, M. Das et al., "Down-regulation of IL-8 by high-dose vitamin D is specific to hyperinflammatory macrophages and involves mechanisms beyond up-regulation of DUSP1," *British Journal of Pharmacology*, vol. 172, no. 19, pp. 4757–4771, 2015.
- [84] A. Zhou, L. Li, G. Zhao et al., "Vitamin D3 inhibits *Helicobacter pylori* infection by activating the Vit D3/VDR-CAMP pathway in mice," *Frontiers in Cellular and Infection Microbiology*, vol. 10, article 566730, 2020.
- [85] Y. Huan, Q. Kong, H. Mou, and H. Yi, "Antimicrobial peptides: classification, design, application and research progress in multiple fields," *Frontiers in Microbiology*, vol. 11, article 582779, 2020.
- [86] K. E. Merriman, M. F. Kweh, J. L. Powell, J. D. Lippolis, and C. D. Nelson, "Multiple beta-defensin genes are upregulated by the vitamin D pathway in cattle," *The Journal of Steroid*



- Biochemistry and Molecular Biology*, vol. 154, pp. 120–129, 2015.
- [87] A. F. Gombart, “The vitamin D-antimicrobial peptide pathway and its role in protection against infection,” *Future Microbiology*, vol. 4, no. 9, pp. 1151–1165, 2009.
- [88] J. F. P. Medeiros, M. V. de Oliveira Borges, A. A. Soares et al., “The impact of vitamin D supplementation on VDR gene expression and body composition in monozygotic twins: randomized controlled trial,” *Scientific Reports*, vol. 10, no. 1, article 11943, 2020.
- [89] L. Guo, W. Chen, H. Zhu et al., “*Helicobacter pylori* induces increased expression of the vitamin D receptor in immune responses,” *Helicobacter*, vol. 19, no. 1, pp. 37–47, 2014.
- [90] C. Chung, P. Silwal, I. Kim, R. L. Modlin, and E. K. Jo, “Vitamin D-cathelicidin axis: at the crossroads between protective immunity and pathological inflammation during infection,” *Immune Network*, vol. 20, no. 2, 2020.
- [91] B. L. Slomiany and A. Slomiany, “*Helicobacter pylori*-induced gastric mucosal TGF- $\alpha$  ectodomain shedding and EGFR transactivation involves Rac 1/p 38 MAPK-dependent TACE activation,” *Inflammopharmacology*, vol. 24, no. 1, pp. 23–31, 2016.
- [92] A. Dusso, M. Cozzolino, Y. Lu, T. Sato, and E. Slatopolsky, “1, 25-Dihydroxyvitamin D downregulation of TGF $\alpha$ /EGFR expression and growth signaling: a mechanism for the anti-proliferative actions of the sterol in parathyroid hyperplasia of renal failure,” *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 89–90, pp. 507–511, 2004.
- [93] Q. Zhang, B. Kanterewicz, S. Shoemaker et al., “Differential response to 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> (1 $\alpha$ ,25(OH)<sub>2</sub>D<sub>3</sub>) in non-small cell lung cancer cells with distinct oncogene mutations,” *The Journal of Steroid Biochemistry and Molecular Biology*, vol. 136, pp. 264–270, 2013.
- [94] F. Zhang, C. Chen, J. Hu et al., “Molecular mechanism of *Helicobacter pylori*-induced autophagy in gastric cancer,” *Oncology Letters*, vol. 18, no. 6, pp. 6221–6227, 2019.
- [95] A. Karkhah, S. Ebrahimpour, M. Rostamtabar et al., “*Helicobacter pylori* evasion strategies of the host innate and adaptive immune responses to survive and develop gastrointestinal diseases,” *Microbiological Research*, vol. 218, pp. 49–57, 2019.
- [96] W. Hu, L. Zhang, M. X. Li et al., “Vitamin D<sub>3</sub> activates the autolysosomal degradation function against *Helicobacter pylori* through the PDIA3 receptor in gastric epithelial cells,” *Autophagy*, vol. 15, no. 4, pp. 707–725, 2019.
- [97] S. W. Kim, D. H. Kim, K. S. Park et al., “Palmitoylation controls trafficking of the intracellular Ca<sup>2+</sup> channel MCOLN3/TRPML3 to regulate autophagy,” *Autophagy*, vol. 15, no. 2, pp. 327–340, 2019.
- [98] K. Hosoda, H. Shimomura, K. Wanibuchi et al., “Identification and characterization of a vitamin D<sub>3</sub> decomposition product bactericidal against *Helicobacter pylori*,” *Scientific Reports*, vol. 5, p. 8860, 2015.
- [99] K. Wanibuchi, K. Hosoda, M. Ihara et al., “Indene compounds synthetically derived from vitamin D have selective antibacterial action on *Helicobacter pylori*,” *Lipids*, vol. 53, no. 4, pp. 393–401, 2018.
- [100] J. W. Chung, J. H. Jeon, S. R. Yoon, and I. Choi, “Vitamin D<sub>3</sub> upregulated protein 1 (VDUP1) is a regulator for redox signaling and stress-mediated diseases,” *The Journal of Dermatology*, vol. 33, no. 10, pp. 662–669, 2006.
- [101] H. J. Kwon, Y. S. Won, H. W. Suh et al., “Vitamin D<sub>3</sub> upregulated protein 1 suppresses TNF- $\alpha$ -induced NF- $\kappa$ B activation in hepatocarcinogenesis,” *The Journal of Immunology*, vol. 185, no. 7, pp. 3980–3989, 2010.
- [102] K. N. Lee, H. S. Kang, J. H. Jeon et al., “VDUP1 is required for the development of natural killer cells,” *Immunity*, vol. 22, no. 2, pp. 195–208, 2005.
- [103] H. J. Kwon, Y. S. Won, K. T. Nam et al., “Vitamin D (3) upregulated protein 1 deficiency promotes N-methyl-N-nitrosourea and *Helicobacter pylori*-induced gastric carcinogenesis in mice,” *Gut*, vol. 61, no. 1, pp. 53–63, 2012.
- [104] T. Gao, M. Zhao, C. Zhang et al., “Association of *Helicobacter pylori* infection with vitamin D deficiency in infants and toddlers,” *The American Journal of Tropical Medicine and Hygiene*, vol. 102, no. 3, pp. 541–546, 2020.
- [105] A. Shafirir, M. Shauly-Aharonov, L. H. Katz, O. Paltiel, Y. Pickman, and Z. Ackerman, “The association between serum vitamin D levels and *Helicobacter pylori* presence and eradication,” *Nutrients*, vol. 13, no. 1, 2021.
- [106] R. Bahşi, V. Atmiş, D. Mut Sürmeli et al., “Effect of *Helicobacter pylori* infection on vitamin D levels in old patients with sarcopenia,” *Advances in Digestive Medicine*, 2020.
- [107] A. Kawaura, E. Takeda, N. Tanida et al., “Inhibitory effect of long term 1 $\alpha$ ,25-dihydroxyvitamin D<sub>3</sub> administration on *Helicobacter pylori* infection,” *Journal of Clinical Biochemistry and Nutrition*, vol. 38, no. 2, pp. 103–106, 2006.
- [108] M. S. El Shahawy, M. H. Hemida, I. El Metwaly, and Z. M. Shady, “The effect of vitamin D deficiency on eradication rates of *Helicobacter pylori* infection,” *JGH Open*, vol. 2, no. 6, pp. 270–275, 2018.
- [109] C. Han, Z. Ni, T. Yuan et al., “Influence of serum vitamin D level on *Helicobacter pylori* eradication: a multi-center, observational, prospective and cohort study,” *Journal of Digestive Diseases*, vol. 20, no. 8, pp. 421–426, 2019.
- [110] B. Huang, S. Yan, C. Chen, and S. Ye, “Effect of 25-hydroxyvitamin D on *Helicobacter pylori* eradication in patients with type 2 diabetes,” *Wiener Klinische Wochenschrift*, vol. 131, no. 3–4, pp. 75–80, 2019.
- [111] R. D. Semba, “The historical evolution of thought regarding multiple micronutrient nutrition,” *The Journal of Nutrition*, vol. 142, no. 1, pp. 143S–156S, 2012.
- [112] Z. Huang, Y. Liu, G. Qi, D. Brand, and S. G. Zheng, “Role of vitamin A in the immune system,” *Journal of Clinical Medicine*, vol. 7, no. 9, 2018.
- [113] S. A. Tanumihardjo, “Vitamin A: biomarkers of nutrition for development,” *The American journal of clinical nutrition*, vol. 94, no. 2, pp. 658S–665S, 2011.
- [114] E. L. Wald, C. M. Badke, L. K. Hintz, M. Spewak, and L. N. Sanchez-Pinto, “Vitamin therapy in sepsis,” *Pediatric Research*, pp. 1–9, 2022.
- [115] M. R. Oliveira, “The neurotoxic effects of vitamin A and retinoids,” *Anais da Academia Brasileira de Ciências*, vol. 87, pp. 1361–1373, 2015.
- [116] M. El Soury, B. E. Fornasari, G. Carta, F. Zen, K. Haastert-Talini, and G. Ronchi, “The role of dietary nutrients in peripheral nerve regeneration,” *International Journal of Molecular Sciences*, vol. 22, no. 14, p. 7417, 2021.
- [117] C. R. Olson and C. V. Mello, “Significance of vitamin A to brain function, behavior and learning,” *Molecular Nutrition & Food Research*, vol. 54, no. 4, pp. 489–495, 2010.

- [118] T. Maoka, "Carotenoids as natural functional pigments," *Journal of Natural Medicines*, vol. 74, no. 1, pp. 1–16, 2020.
- [119] D. D. Miller and R. M. Welch, "Food system strategies for preventing micronutrient malnutrition," *Food Policy*, vol. 42, pp. 115–128, 2013.
- [120] B. D. Ribeiro, D. W. Barreto, and M. A. Z. Coelho, "Technological aspects of  $\beta$ -carotene production," *Food and Bioprocess Technology*, vol. 4, no. 5, pp. 693–701, 2011.
- [121] J. Salgueiro, M. Zubillaga, C. Goldman et al., "Review article: is there a link between micronutrient malnutrition and *Helicobacter pylori* infection?," *Alimentary Pharmacology & Therapeutics*, vol. 20, no. 10, pp. 1029–1034, 2004.
- [122] T. Grune, G. Lietz, A. Palou et al., "Beta-carotene is an important vitamin A source for humans," *The Journal of nutrition*, vol. 140, no. 12, pp. 2268s–2285s, 2010.
- [123] L. M. Oliveira, F. M. E. Teixeira, and M. N. Sato, "Impact of retinoic acid on immune cells and inflammatory diseases," *Mediators of Inflammation*, vol. 2018, Article ID 3067126, 17 pages, 2018.
- [124] M. Iwata, A. Hirakiyama, Y. Eshima, H. Kagechika, C. Kato, and S. Y. Song, "Retinoic acid imprints gut-homing specificity on T cells," *Immunity*, vol. 21, no. 4, pp. 527–538, 2004.
- [125] M. R. Bono, G. Tejon, F. Flores-Santibanez, D. Fernandez, M. Roseblatt, and D. Sauma, "Retinoic acid as a modulator of T cell immunity," *Nutrients*, vol. 8, no. 6, 2016.
- [126] S. B. Ghavami, A. Yadegar, H. A. Aghdaei et al., "Immunomodulation and generation of tolerogenic dendritic cells by probiotic bacteria in patients with inflammatory bowel disease," *International journal of molecular sciences*, vol. 21, no. 17, 2020.
- [127] P. H. De Medeiros, D. V. Pinto, J. Z. De Almeida et al., "Modulation of intestinal immune and barrier functions by vitamin A: implications for current understanding of malnutrition and enteric infections in children," *Nutrients*, vol. 10, no. 9, 2018.
- [128] D. M. Duriancik, D. E. Lackey, and K. A. Hoag, "Vitamin A as a regulator of antigen presenting cells," *The Journal of Nutrition*, vol. 140, no. 8, pp. 1395–1399, 2010.
- [129] S. Mahassni and N. Al-Shaikh, "Effects of vitamin A overdose on rat's organs involved in immunity and vitamin A storage," *Acta Alimentaria*, vol. 43, no. 3, pp. 452–458, 2014.
- [130] T. Bohn, C. Desmarchelier, S. N. el et al., " $\beta$ -Carotene in the human body: metabolic bioactivation pathways - from digestion to tissue distribution and excretion," *The Proceedings of the Nutrition Society*, vol. 78, no. 1, pp. 68–87, 2019.
- [131] S. H. Jang, J. W. Lim, and H. Kim, "Beta-carotene inhibits *Helicobacter pylori*-induced expression of inducible nitric oxide synthase and cyclooxygenase-2 in human gastric epithelial AGS cells," *Journal of Physiology and Pharmacology*, vol. 60, Suppl 7, pp. 131–137, 2009.
- [132] Y. Park, H. Lee, J. W. Lim, and H. Kim, "Inhibitory effect of  $\beta$ -carotene on *Helicobacter pylori*-induced TRAF expression and hyper-proliferation in gastric epithelial cells," *Antioxidants*, vol. 8, no. 12, p. 637, 2019.
- [133] S. Bae, J. W. Lim, and H. Kim, "beta-Carotene inhibits expression of matrix metalloproteinase-10 and invasion in *Helicobacter pylori*-infected gastric epithelial cells," *Molecules*, vol. 26, no. 6, 2021.
- [134] D. Kim, J. W. Lim, and H. Kim, "beta-Carotene inhibits expression of c-Myc and Cyclin E in *Helicobacter pylori*-infected gastric epithelial cells," *Journal of Cancer Prevention*, vol. 24, no. 3, pp. 192–196, 2019.
- [135] H. Kang and H. Kim, "Astaxanthin and beta-carotene in *Helicobacter pylori*-induced gastric inflammation: a mini-review on action mechanisms," *Journal of Cancer Prevention*, vol. 22, no. 2, pp. 57–61, 2017.
- [136] H. Lee, J. W. Lim, and H. Kim, "Effect of astaxanthin on activation of autophagy and inhibition of apoptosis in *Helicobacter pylori*-infected gastric epithelial cell line AGS," *Nutrients*, vol. 12, no. 6, 2020.
- [137] C. Miodownik and V. Lerner, "The neuroprotective efficacy of vitamins," in *Brain protection in schizophrenia, mood and cognitive disorders*, pp. 505–553, Springer, 2010.
- [138] I. R. Sequeira, "Higher doses of ascorbic acid may have the potential to promote nutrient delivery via intestinal paracellular absorption," *World Journal of Gastroenterology*, vol. 27, no. 40, pp. 6750–6756, 2021.
- [139] S. J. Padayatty and M. Levine, "Vitamin C: the known and the unknown and Goldilocks," *Oral Diseases*, vol. 22, no. 6, pp. 463–493, 2016.
- [140] M. Doseděl, E. Jirkovský, K. Macáková et al., "Vitamin C- Sources, Physiological Role, Kinetics, Deficiency, Use, Toxicity, and Determination," *Nutrients*, vol. 13, no. 2, p. 615, 2021.
- [141] E. A. Miles and P. C. Calder, "Effects of citrus fruit juices and their bioactive components on inflammation and immunity: a narrative review," *Frontiers in Immunology*, vol. 12, no. 2558, 2021.
- [142] E. S. Wintergerst, S. Maggini, and D. H. Hornig, "Contribution of selected vitamins and trace elements to immune function," *Annals of Nutrition & Metabolism*, vol. 51, no. 4, pp. 301–323, 2007.
- [143] A. C. Carr and S. Maggini, "Vitamin C and Immune Function," *Nutrients*, vol. 9, no. 11, 2017.
- [144] A. T. Otten, A. R. Bourgonje, V. Peters, B. Z. Alizadeh, and G. Dijkstra, "Harmsen HJM. Vitamin C supplementation in healthy individuals leads to shifts of bacterial populations in the gut-a pilot study," *Antioxidants (Basel)*, vol. 10, no. 8, 2021.
- [145] A. Kawashima, A. Sekizawa, K. Koide et al., "Vitamin C induces the reduction of oxidative stress and paradoxically stimulates the apoptotic gene expression in extravillous trophoblasts derived from first-trimester tissue," *Reproductive Sciences*, vol. 22, no. 7, pp. 783–790, 2015.
- [146] M. Yoshinaga, A. Ohtani, N. Harada, Y. Fukuda, and H. Nawata, "Vitamin C inhibits corpus gastritis in *Helicobacter pylori*-infected patients during acid-suppressive therapy," *Journal of Gastroenterology and Hepatology*, vol. 16, no. 11, pp. 1206–1210, 2001.
- [147] A. Hussain, E. Tabrez, J. Peela, P. D. Honnavar, and T. SSM, "Vitamin C: a preventative, therapeutic agent against *Helicobacter pylori*," *Cureus*, vol. 10, no. 7, article e3062, 2018.
- [148] Z. W. Zhang and M. J. Farthing, "The roles of vitamin C in *Helicobacter pylori* associated gastric carcinogenesis," *Chinese Journal of Digestive Diseases*, vol. 6, no. 2, pp. 53–58, 2005.
- [149] N. J. Satheesh, S. M. Samuel, and D. Büsselberg, "Combination therapy with vitamin C could eradicate cancer stem cells," *Biomolecules*, vol. 10, no. 1, 2020.
- [150] P. S. Phull, A. B. Price, K. L. White, C. J. Schorah, and M. R. Jacyna, "Gastrointestinal mucosal vitamin-C levels in

- Helicobacter pylori* infection,” *Scandinavian Journal of Gastroenterology*, vol. 34, no. 4, pp. 361–366, 1999.
- [151] S. Sasazuki, S. Sasaki, Y. Tsubono et al., “The effect of 5-year vitamin C supplementation on serum pepsinogen level and *Helicobacter pylori* infection,” *Cancer Science*, vol. 94, no. 4, pp. 378–382, 2003.
- [152] G. Capurso, R. Ricci, F. Panzuto et al., “Intragastric ascorbic but not uric acid is depleted in relation with the increased pH in patients with atrophic body gastritis and *H. pylori* gastritis,” *Helicobacter*, vol. 8, no. 4, pp. 300–306, 2003.
- [153] M. Woodward, H. Tunstall-Pedoe, and K. McColl, “*Helicobacter pylori* infection reduces systemic availability of dietary vitamin C,” *European Journal of Gastroenterology & Hepatology*, vol. 13, no. 3, pp. 233–237, 2001.
- [154] H. R. Feiz and S. Mobarhan, “Does vitamin C intake slow the progression of gastric cancer in *Helicobacter pylori*-infected populations?,” *Nutrition Reviews*, vol. 60, no. 1, pp. 34–36, 2002.
- [155] T. Rokkas, S. Ladas, C. Liatsos et al., “Relationship of *Helicobacter pylori* Cag A(+) status to gastric juice vitamin C levels,” *European Journal of Clinical Investigation*, vol. 29, no. 1, pp. 56–62, 1999.
- [156] J. A. Simon, E. S. Hudes, and G. I. Perez-Perez, “Relation of serum ascorbic acid to *Helicobacter pylori* serology in US adults: the Third National Health and Nutrition Examination Survey,” *Journal of the American College of Nutrition*, vol. 22, no. 4, pp. 283–289, 2003.
- [157] H. Mei and H. Tu, “Vitamin C and *Helicobacter pylori* infection: current knowledge and future prospects,” *Frontiers in Physiology*, vol. 9, p. 1103, 2018.
- [158] M. G. Traber, “Vitamin E regulatory mechanisms,” *Annual Review of Nutrition*, vol. 27, pp. 347–362, 2007.
- [159] L. Schmolz, M. Birringer, S. Lorkowski, and M. Wallert, “Complexity of vitamin E metabolism,” *World Journal of Biological Chemistry*, vol. 7, no. 1, pp. 14–43, 2016.
- [160] I. Mozos, D. Stoian, and C. T. Luca, “Crosstalk between vitamins A, B12, D, K, C, and E status and arterial stiffness,” *Disease Markers*, vol. 2017, 14 pages, 2017.
- [161] S. Rizvi, S. T. Raza, F. Ahmed, A. Ahmad, S. Abbas, and F. Mahdi, “The role of vitamin e in human health and some diseases,” *Sultan Qaboos University Medical Journal*, vol. 14, no. 2, pp. e157–e165, 2014.
- [162] A. C. Howard, A. K. McNeil, and P. L. McNeil, “Promotion of plasma membrane repair by vitamin E,” *Nature Communications*, vol. 2, p. 597, 2011.
- [163] D. Raederstorff, A. Wyss, P. C. Calder, P. Weber, and M. Eggersdorfer, “Vitamin E function and requirements in relation to PUFA,” *The British Journal of Nutrition*, vol. 114, no. 8, pp. 1113–1122, 2015.
- [164] A. Azzi, “The role of alpha-tocopherol in preventing disease,” *European journal of nutrition*, vol. 43, Suppl 1, pp. I/18–I/25, 2004.
- [165] E. D. Lewis, S. N. Meydani, and D. Wu, “Regulatory role of vitamin E in the immune system and inflammation,” *IUBMB Life*, vol. 71, no. 4, pp. 487–494, 2019.
- [166] D. Wu, E. D. Lewis, M. Pae, and S. N. Meydani, “Nutritional modulation of immune function: analysis of evidence, mechanisms, and clinical relevance,” *Frontiers in Immunology*, vol. 9, p. 3160, 2018.
- [167] G. Y. Lee and S. N. Han, “The Role of Vitamin E in Immunity,” *Nutrients*, vol. 10, no. 11, 2018.
- [168] N. Sugimoto, N. Yoshida, Y. Nakamura et al., “Influence of vitamin E on gastric mucosal injury induced by *Helicobacter pylori* infection,” *BioFactors*, vol. 28, no. 1, pp. 9–19, 2006.
- [169] Y. Q. Sun, I. Girgensone, P. Leanderson, F. Petersson, and K. Borch, “Effects of antioxidant vitamin supplements on *Helicobacter pylori*-induced gastritis in Mongolian gerbils,” *Helicobacter*, vol. 10, no. 1, pp. 33–42, 2005.
- [170] H. M. Zhang, N. Wakisaka, O. Maeda, and T. Yamamoto, “Vitamin C inhibits the growth of a bacterial risk factor for gastric carcinoma: *Helicobacter pylori*,” *Cancer*, vol. 80, no. 10, pp. 1897–1903, 1997.
- [171] M. Sezikli, Z. A. Cetinkaya, F. Guzelbulut, A. Yesil, S. Cosgun, and O. O. Kurdas, “Supplementing vitamins C and E to standard triple therapy for the eradication of *Helicobacter pylori*,” *Journal of Clinical Pharmacy and Therapeutics*, vol. 37, no. 3, pp. 282–285, 2012.
- [172] M. Sezikli, Z. A. Çetinkaya, H. Sezikli et al., “Oxidative stress in *Helicobacter pylori* infection: does supplementation with vitamins C and E increase the eradication rate?,” *Helicobacter*, vol. 14, no. 4, pp. 280–285, 2009.
- [173] G. Li, L. Li, C. Yu, and L. Chen, “Effect of vitamins C and E supplementation on *Helicobacter pylori* eradication: a meta-analysis,” *The British Journal of Nutrition*, vol. 106, no. 11, pp. 1632–1637, 2011.
- [174] H. Demirci, S. Uygun İlikhan, K. Öztürk et al., “Influence of vitamin C and E supplementation on the eradication rates of triple and quadruple eradication regimens for *Helicobacter pylori* infection,” *The Turkish Journal of Gastroenterology*, vol. 26, no. 6, pp. 456–460, 2015.
- [175] E. Y. Caicedo Ochoa, C. O. Quintero Moreno, Y. R. Méndez Fandiño, S. C. Sánchez Fonseca, H. F. Cortes Motta, and S. A. Guio Guerra, “Assessment of the use of vitamin C and E supplements concomitantly to antibiotic treatment against *Helicobacter pylori*: a systematic review and meta-analysis,” *Medicina Clínica (Barcelona)*, vol. 151, no. 2, pp. 45–52, 2018.
- [176] C. H. Chuang, B. S. Sheu, A. H. Huang, H. B. Yang, and J. J. Wu, “Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible *Helicobacter pylori* infection,” *Helicobacter*, vol. 7, no. 5, pp. 310–316, 2002.
- [177] H. Sies and W. Stahl, “Vitamins E and C, beta-carotene, and other carotenoids as antioxidants,” *The American journal of clinical nutrition*, vol. 62, no. 6, pp. 1315S–1321S, 1995.
- [178] P. Phull, A. Price, M. Thorniley, C. Green, and M. Jacyna, “Vitamin E concentrations in the human stomach and duodenum—correlation with *Helicobacter pylori* infection,” *Gut*, vol. 39, no. 1, pp. 31–35, 1996.
- [179] S. M. Everett, I. M. Drake, K. L. M. White et al., “Antioxidant vitamin supplements do not reduce reactive oxygen species activity in *Helicobacter pylori* gastritis in the short term,” *The British Journal of Nutrition*, vol. 87, no. 1, pp. 3–11, 2002.
- [180] S. A. Kaboli, H. Zojaji, D. Mirsattari et al., “Effect of addition of vitamin C to clarithromycin-amoxicillin-omeprazol triple regimen on *Helicobacter pylori* eradication,” *Acta Gastroenterologica Belgica*, vol. 72, no. 2, pp. 222–224, 2009.
- [181] H. Zojaji, R. Talaie, D. Mirsattari et al., “The efficacy of *Helicobacter pylori* eradication regimen with and without vitamin C supplementation,” *Digestive and Liver Disease*, vol. 41, no. 9, pp. 644–647, 2009.



- [182] M. Sezikli, Z. A. Cetinkaya, F. Guzelbulut et al., "Efficacy of vitamins supplementation to therapy on *Helicobacter pylori* eradication in patients with low antioxidant capacity," *Clinics and Research in Hepatology and Gastroenterology*, vol. 35, no. 11, pp. 745–749, 2011.
- [183] M. S. El Shahawy, I. El Metwaly, and Z. M. Shady, "Value of supplementing vitamin C to the triple therapy on the eradication rates of *Helicobacter pylori* infection," *Advances in Digestive Medicine*, vol. 7, no. 3, pp. 124–131, 2020.
- [184] D. O. Kennedy, "B vitamins and the brain: mechanisms, dose and efficacy—a review," *Nutrients*, vol. 8, no. 2, p. 68, 2016.
- [185] K. Yoshii, K. Hosomi, K. Sawane, and J. Kunisawa, "Metabolism of dietary and microbial vitamin B family in the regulation of host immunity," *Frontiers in Nutrition*, vol. 6, p. 48, 2019.
- [186] R. Obeid, S. G. Heil, M. M. A. Verhoeven, E. van den Heuvel, L. de Groot, and S. Eussen, "Vitamin B12 intake from animal foods, biomarkers, and health aspects," *Frontiers in Nutrition*, vol. 6, p. 93, 2019.
- [187] J. Kunisawa and H. Kiyono, "Vitamin-mediated regulation of intestinal immunity," *Frontiers in Immunology*, vol. 4, p. 189, 2013.
- [188] I. Abe, K. Shirato, Y. Hashizume et al., "Folate-deficiency induced cell-specific changes in the distribution of lymphocytes and granulocytes in rats," *Environmental Health and Preventive Medicine*, vol. 18, no. 1, pp. 78–84, 2013.
- [189] J. Kunisawa, E. Hashimoto, I. Ishikawa, and H. Kiyono, "A pivotal role of vitamin B9 in the maintenance of regulatory T cells in vitro and in vivo," *PLoS One*, vol. 7, no. 2, article e32094, 2012.
- [190] P. C. Calder, "Nutrition, immunity and COVID-19," *BMJ Nutr Prev Health*, vol. 3, no. 1, pp. 74–92, 2020.
- [191] S. Maggini, E. S. Wintergerst, S. Beveridge, and D. H. Hornig, "Selected vitamins and trace elements support immune function by strengthening epithelial barriers and cellular and humoral immune responses," *The British Journal of Nutrition*, vol. 98, Supplement 1, pp. S29–S35, 2007.
- [192] E. Tourkochristou, C. Triantos, and A. Mouzaki, "The influence of nutritional factors on immunological outcomes," *Frontiers in Immunology*, vol. 12, article 665968, 2021.
- [193] J. Dierkes, M. Ebert, P. Malferteiner, and C. Luley, "*Helicobacter pylori* infection, vitamin B12 and homocysteine," *Digestive Diseases*, vol. 21, no. 3, pp. 237–244, 2003.
- [194] H. Cohen, W. Weinstein, and R. Carmel, "Heterogeneity of gastric histology and function in food cobalamin malabsorption: absence of atrophic gastritis and achlorhydria in some patients with severe malabsorption," *Gut*, vol. 47, no. 5, pp. 638–645, 2000.
- [195] O. Shuval-Sudai and E. Granot, "An association between *Helicobacter pylori* infection and serum vitamin B12 levels in healthy adults," *Journal of Clinical Gastroenterology*, vol. 36, no. 2, pp. 130–133, 2003.
- [196] K. Ravi, J. Joseph, and D. M. Thomas, "*Helicobacter pylori* infection and vitamin B-12 deficiency—a cross sectional study," *Asian Journal of Medical Sciences*, vol. 8, no. 4, pp. 16–20, 2017.
- [197] S. P. Stabler and R. H. Allen, "Vitamin B12 deficiency as a worldwide problem," *Annual Review of Nutrition*, vol. 24, pp. 299–326, 2004.
- [198] A. Izzotti, P. Durando, F. Ansaldi, F. Gianiorio, and A. Pulliero, "Interaction between *Helicobacter pylori*, diet, and genetic polymorphisms as related to non-cancer diseases," *Mutation Research, Fundamental and Molecular Mechanisms of Mutagenesis*, vol. 667, no. 1–2, pp. 142–157, 2009.
- [199] M. Akcam, S. Ozdem, A. Yilmaz, M. Gultekin, and R. Artan, "Serum ferritin, vitamin B (12), folate, and zinc levels in children infected with *Helicobacter pylori*," *Digestive Diseases and Sciences*, vol. 52, no. 2, pp. 405–410, 2007.
- [200] S. J. F. Cronin, C. J. Woolf, G. Weiss, and J. M. Penninger, "The role of iron regulation in immunometabolism and immune-related disease," *Frontiers in Molecular Biosciences*, vol. 6, p. 116, 2019.
- [201] J. Arnhold, P. G. Furtmuller, and C. Obinger, "Redox properties of myeloperoxidase," *Redox Report*, vol. 8, no. 4, pp. 179–186, 2003.
- [202] M. Nairz and G. Weiss, "Iron in infection and immunity," *Molecular Aspects of Medicine*, vol. 75, article 100864, 2020.
- [203] M. Y. Xu, B. Cao, B. S. Yuan, J. Yin, L. Liu, and Q. B. Lu, "Association of anaemia with *Helicobacter pylori* infection: a retrospective study," *Scientific Reports*, vol. 7, no. 1, article 13434, 2017.
- [204] K. Haile, T. Yemane, G. Tesfaye, D. Wolde, A. Timerga, and A. Haile, "Anemia and its association with *Helicobacter pylori* infection among adult dyspeptic patients attending Wachemo University Nigist Eleni Mohammad Memorial Referral Hospital, Southwest Ethiopia: a cross-sectional study," *PLoS One*, vol. 16, no. 1, article e0245168, 2021.
- [205] A. Hassan, K. K. Sada, S. Ketheeswaran, A. K. Dubey, and M. S. Bhat, "Role of zinc in mucosal health and disease: a review of physiological, biochemical, and molecular processes," *Cureus*, vol. 12, no. 5, 2020.
- [206] D. Skrajnowska and B. Bobrowska-Korczak, "Role of zinc in immune system and anti-cancer defense mechanisms," *Nutrients*, vol. 11, no. 10, 2019.
- [207] N. Z. Gammoh and L. Rink, "Zinc in infection and inflammation," *Nutrients*, vol. 9, no. 6, p. 624, 2017.
- [208] H. Haase and L. Rink, "The immune system and the impact of zinc during aging," *Immunity & Ageing*, vol. 6, p. 9, 2009.
- [209] J. A. Gaddy, J. N. Radin, J. T. Loh et al., "The host protein calprotectin modulates the *Helicobacter pylori* cag type IV secretion system via zinc sequestration," *PLoS Pathogens*, vol. 10, no. 10, article e1004450, 2014.
- [210] K. P. Haley and J. A. Gaddy, "Metalloregulation of *Helicobacter pylori* physiology and pathogenesis," *Frontiers in Microbiology*, vol. 6, p. 911, 2015.
- [211] Z. Huang, A. H. Rose, and P. R. Hoffmann, "The role of selenium in inflammation and immunity: from molecular mechanisms to therapeutic opportunities," *Antioxidants & Redox Signaling*, vol. 16, no. 7, pp. 705–743, 2012.
- [212] J. C. Avery and P. R. Hoffmann, "Selenium, selenoproteins, and immunity," *Nutrients*, vol. 10, no. 9, 2018.
- [213] B. A. Carlson, M. H. Yoo, R. K. Shrimali et al., "Role of selenium-containing proteins in T-cell and macrophage function," *The Proceedings of the Nutrition Society*, vol. 69, no. 3, pp. 300–310, 2010.
- [214] A. S. Durmus, H. Yildiz, I. Yaman, and H. Simsek, "Efficacy of vitamin E and selenium for the prevention of intra-abdominal adhesions in rats: uterine horn models," *Clinics*, vol. 66, no. 7, pp. 1247–1251, 2011.



- [215] S. S. Percival, "Copper and immunity," *The American Journal of Clinical Nutrition*, vol. 67, Supplement 5, pp. 1064S–1068S, 1998.
- [216] M. C. Wu, C. Y. Huang, F. C. Kuo et al., "The effect of *Helicobacter pylori* eradication on the levels of essential trace elements," *BioMed Research International*, vol. 2014, Article ID 513725, 5 pages, 2014.
- [217] T. Hu, H. Xu, C. Wang, H. Qin, and Z. An, "Magnesium enhances the chondrogenic differentiation of mesenchymal stem cells by inhibiting activated macrophage-induced inflammation," *Scientific Reports*, vol. 8, no. 1, p. 3406, 2018.
- [218] A. A. Zheltova, M. V. Kharitonova, I. N. Iezhitsa, and A. A. Spasov, "Magnesium deficiency and oxidative stress: an update," *Biomedicine*, vol. 6, no. 4, p. 20, 2016.
- [219] M. Tam, S. Gomez, M. Gonzalez-Gross, and A. Marcos, "Possible roles of magnesium on the immune system," *European Journal of Clinical Nutrition*, vol. 57, no. 10, pp. 1193–1197, 2003.
- [220] J. L. Ford, N. O. Kaakoush, and G. L. Mendz, "Phosphonate metabolism in *Helicobacter pylori*," *Antonie Van Leeuwenhoek*, vol. 97, no. 1, pp. 51–60, 2010.
- [221] F. Salsano, C. Francia, I. Roumpedaki et al., "Immune effects of nickel," *International Journal of Immunopathology and Pharmacology*, vol. 17, Supplement 2, pp. 63–69, 2004.
- [222] J. Y. Kim, K. Huh, K. Y. Lee, J. M. Yang, and T. J. Kim, "Nickel induces secretion of IFN-gamma by splenic natural killer cells," *Experimental & Molecular Medicine*, vol. 41, no. 4, pp. 288–295, 2009.
- [223] M. Campanale, E. Nucera, V. Ojetti et al., "Nickel free-diet enhances the *Helicobacter pylori* eradication rate: a pilot study," *Digestive Diseases and Sciences*, vol. 59, no. 8, pp. 1851–1855, 2014.
- [224] C. Camaschella, A. Nai, and L. Silvestri, "Iron metabolism and iron disorders revisited in the hepcidin era," *Haematologica*, vol. 105, no. 2, pp. 260–272, 2020.
- [225] Z. Kopec, R. R. Starzynski, A. Jonczy, R. Mazgaj, and P. Lipinski, "Role of iron metabolism-related genes in prenatal development: insights from mouse transgenic models," *Genes*, vol. 12, no. 9, 2021.
- [226] E. P. Skaar and M. Raffatellu, "Metals in infectious diseases and nutritional immunity," *Metallomics*, vol. 7, no. 6, pp. 926–928, 2015.
- [227] Y. Xia, Y. Li, X. Wu et al., "Ironing out the details: how iron orchestrates macrophage polarization," *Frontiers in Immunology*, vol. 12, p. 1712, 2021.
- [228] H. Monzón, M. Forné, M. Esteve et al., "*Helicobacter pylori* infection as a cause of iron deficiency anaemia of unknown origin," *World Journal of Gastroenterology*, vol. 19, no. 26, pp. 4166–4171, 2013.
- [229] V. M. Cardenas, Z. D. Mulla, M. Ortiz, and D. Y. Graham, "Iron deficiency and *Helicobacter pylori* infection in the United States," *American Journal of Epidemiology*, vol. 163, no. 2, pp. 127–134, 2006.
- [230] S. John, J. D. Baltodano, N. Mehta, K. Mark, and U. Murthy, "Unexplained iron deficiency anemia: does *Helicobacter pylori* have a role to play?," *Gastroenterology Report*, vol. 6, no. 3, pp. 215–220, 2018.
- [231] D. M. E. Demerdash, H. Ibrahim, D. M. Hassan, H. Moustafa, and N. M. Tawfik, "*Helicobacter pylori* associated to unexplained or refractory iron deficiency anemia: an Egyptian single-center experience," *Hematology, Transfusion and Cell Therapy*, vol. 40, no. 3, pp. 219–225, 2018.
- [232] M. Maares and H. Haase, "A guide to human zinc absorption: general overview and recent advances of in vitro intestinal models," *Nutrients*, vol. 12, no. 3, p. 762, 2020.
- [233] T. E. Kehl-Fie and E. P. Skaar, "Nutritional immunity beyond iron: a role for manganese and zinc," *Current Opinion in Chemical Biology*, vol. 14, no. 2, pp. 218–224, 2010.
- [234] T. Hara, T. A. Takeda, T. Takagishi, K. Fukue, T. Kambe, and T. Fukada, "Physiological roles of zinc transporters: molecular and genetic importance in zinc homeostasis," *The Journal of Physiological Sciences*, vol. 67, no. 2, pp. 283–301, 2017.
- [235] W. Maret and H. H. Sandstead, "Zinc requirements and the risks and benefits of zinc supplementation," *Journal of Trace Elements in Medicine and Biology*, vol. 20, no. 1, pp. 3–18, 2006.
- [236] F. Sempertegui, M. Diaz, R. Mejia et al., "Low concentrations of zinc in gastric mucosa are associated with increased severity of *Helicobacter pylori*-induced inflammation," *Helicobacter*, vol. 12, no. 1, pp. 43–48, 2007.
- [237] D. M. Minich and B. I. Brown, "A review of dietary (phyto) nutrients for glutathione support," *Nutrients*, vol. 11, no. 9, p. 2073, 2019.
- [238] C. Liu and R. M. Russell, "Nutrition and gastric cancer risk: an update," *Nutrition Reviews*, vol. 66, no. 5, pp. 237–249, 2008.
- [239] M. C. Camargo, R. F. Burk, L. E. Bravo et al., "Plasma selenium measurements in subjects from areas with contrasting gastric cancer risks in Colombia," *Archives of Medical Research*, vol. 39, no. 4, pp. 443–451, 2008.
- [240] N. Ozturk, N. Kurt, F. B. Ozgeris et al., "Serum Zinc, copper, magnesium and selenium levels in children with *Helicobacter pylori* infection," *The Eurasian Journal of Medicine*, vol. 47, no. 2, pp. 126–129, 2015.
- [241] H. Steinbrenner, S. Al-Quraishy, M. A. Dkhil, F. Wunderlich, and H. Sies, "Dietary selenium in adjuvant therapy of viral and bacterial infections," *Advances in Nutrition*, vol. 6, no. 1, pp. 73–82, 2015.
- [242] B. R. Stern, "Essentiality and toxicity in copper health risk assessment: overview, update and regulatory considerations," *Journal of Toxicology and Environmental Health, Part A*, vol. 73, no. 2-3, pp. 114–127, 2010.
- [243] M. Shike, "Copper in parenteral nutrition," *Gastroenterology*, vol. 137, no. 5, pp. S13–S17, 2009.
- [244] K. Y. Djoko, C. L. Ong, M. J. Walker, and A. G. McEwan, "The role of copper and zinc toxicity in innate immune defense against bacterial pathogens," *The Journal of Biological Chemistry*, vol. 290, no. 31, pp. 18954–18961, 2015.
- [245] M. A. Janjetic, C. G. Goldman, N. E. Balcarce et al., "Iron, zinc, and copper nutritional status in children infected with *Helicobacter pylori*," *Journal of Pediatric Gastroenterology and Nutrition*, vol. 51, no. 1, pp. 85–89, 2010.
- [246] J. Pfeiffer, J. Guhl, B. Waidner, M. Kist, and S. Bereswill, "Magnesium uptake by Cor A is essential for viability of the gastric pathogen *Helicobacter pylori*," *Infection and Immunity*, vol. 70, no. 7, pp. 3930–3934, 2002.
- [247] J. Auwerx, P. Rybarczyk, P. Kischel et al., "Mg<sup>2+</sup> transporters in digestive cancers," *Nutrients*, vol. 13, no. 1, p. 210, 2021.

- [248] A. A. Mathew and R. Panonnummal, "Magnesium'-the master cation-as a drug-possibilities and evidences," *Biometals*, vol. 34, no. 5, pp. 955–986, 2021.
- [249] A. Kim, S. Park, and J. H. Sung, "Cell viability and immune response to low concentrations of nickel and cadmium: an in vitro model," *International Journal of Environmental Research and Public Health*, vol. 17, no. 24, 2020.
- [250] A. Cavani, F. Nasorri, C. Ottaviani, S. Sebastiani, O. De Pita, and G. Girolomoni, "Human CD25+ regulatory T cells maintain immune tolerance to nickel in healthy, nonallergic individuals," *Journal of Immunology*, vol. 171, no. 11, pp. 5760–5768, 2003.
- [251] A. A. Schmalstig, S. L. Benoit, S. K. Misra, J. S. Sharp, and R. J. Maier, "Noncatalytic antioxidant role for *Helicobacter pylori* urease," *Journal of Bacteriology*, vol. 200, no. 17, 2018.
- [252] K. P. Haley and J. A. Gaddy, "Nutrition and *Helicobacter pylori*: host diet and nutritional immunity influence bacterial virulence and disease outcome," *Gastroenterology Research and Practice*, vol. 2016, Article ID 3019362, 10 pages, 2016.
- [253] F. N. Stähler, S. Odenbreit, R. Haas et al., "The novel *Helicobacter pylori* Czn ABC metal efflux pump is required for cadmium, zinc, and nickel resistance, urease modulation, and gastric colonization," *Infection and Immunity*, vol. 74, no. 7, pp. 3845–3852, 2006.
- [254] H. De Reuse, D. Vinella, and C. Cavazza, "Common themes and unique proteins for the uptake and trafficking of nickel, a metal essential for the virulence of *Helicobacter pylori*," *Frontiers in Cellular and Infection Microbiology*, vol. 3, p. 94, 2013.
- [255] L. Wolfram, E. Haas, and P. Bauerfeind, "Nickel represses the synthesis of the nickel permease Nix A of *Helicobacter pylori*," *Journal of Bacteriology*, vol. 188, no. 4, pp. 1245–1250, 2006.
- [256] J. Stoof, E. J. Kuipers, G. Klaver, and A. H. van Vliet, "An ABC transporter and a Ton B ortholog contribute to *Helicobacter mustelae* nickel and cobalt acquisition," *Infection and Immunity*, vol. 78, no. 10, pp. 4261–4267, 2010.
- [257] M. Denic, E. Turlin, V. Michel et al., "A novel mode of control of nickel uptake by a multifunctional metallochaperone," *PLoS Pathogens*, vol. 17, no. 1, article e1009193, 2021.